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1Summary
Uterine leiomyomas (UL), as the most common gynecologic tumors in women, with a
mesenchymal origin, are attended scientifically due to their high prevalence,
irrecoverable complications, and their high therapeutic burden. Genetic factors are
among the factors playing an important role in the initiation of these tumors.
This thesis aims at the cytogenetic molecular investigations in a large series of UL
(N=261), aimed to a better understanding of the correlation between chromosomal
changes and the expression of related genes, as well as the genome instability in
correlation with these genes. This work is divided into: chromosome analyses,
molecular tests including quantification of the expression of HMGA genes by using
real-time quantitative RT-PCR, long-term in vitro expansion of myoma cells, and
survey of genome stability in UL.
This study has discovered that:
From a total of 261 UL, 29.1% showed an abnormal karyotype by conventional
cytogenetic techniques. The abnormalities are correlated with tumor size and
an overexpression of HMGA genes in two major cytogenetic subgroups.
HMGA2 was overexpressed in the myomas with 12q14~15 rearrangements in
comparison with matched myometrium and cytogenetically normal tumors.
The overexpression of HMGA2 was also observed in normal UL compared
with myometrial tissue that shows a general role of HMGA2 overexpression in
the pathogenesis of UL.
Expression of HMGA1 was observed in a higher level in the myomas with 6p21
aberrations than that in myometrium and normal UL.
Increase of the average expression of HMGA1 mRNA in UL with 6p21
rearrangements was much less stronger than that of HMGA2 mRNA in case of
12q14~15 aberrations.
Long-term culture of myoma cells with different levels of HMGA proteins did
not result in immortalization of these cells, even the existence of a high
proliferative rate in the cells with an overexpression of HMGA2.
Based on the investigations concerning genome stability in UL, no correlation
between HMGA2 level and the increase of genomic instability was shown. This
raises doubts about a protection maybe by other factors accompanied with a
high HMGA2.
2Further studies are still recommended in this area. Concerning the high homology of
HMGA2 and HMGA1 proteins, it seems possible that HMGA1 leaves more effects on
the developements of UL.
Nevertheless, it is suggested to do more detailed analyses of the HMGA1 gene
expression and protein levels. Moreover, further investigations on other factors
involved in cell growth and correlated with HMGA proteins are necessary.
3Zusammenfassung
Uterusleiomyome (UL), als die häufigsten gynäkologischen Tumoren bei Frauen, mit
einem mesenchymalen Ursprung, sind aufgrund ihres häufigen Vorkommens, ihrer
schwer behandelbaren Komplikationen und ihres hohen therapeutischen Aufwandes
ins Interessenfeld der Wissenschaft gerückt. Genetische Faktoren spielen unter
anderen Faktoren eine sehr wichtige Rolle bei der Entstehung dieser Tumoren.
Ziel dieser Arbeit sind zytogenetische und molekulare Untersuchungen an einer
großen Anzahl von UL (N = 261), um sowohl ein besseres Verständnis des
Zusammenhangs zwischen den chromosomalen Veränderungen und der Expression
der betroffenen Gene, HMGA1 und HMGA2, als auch den Zusammenhang zwischen
der Genominstabilität und denselben Genen zu ermöglichen. Diese Arbeit gliedert
sich in: Analyse der Chromosomen, molekulare Untersuchungen einschließlich der
Quantifizierung der Expression von HMGA Genen mit Hilfe von quantitativer Real-
Time RT-PCR, Langzeitkultivierung von Myomzellen in vitro und Untersuchung der
Genomstabilität in UL.
Diese Studie hat Folgendes herausgefunden:
Unter Verwendung konventionellen zytogenetischen Techniken zeigten 29,1%
aller untersuchten UL einen aberranten Karyotyp. In zwei wesentlichen
zytogenetischen Subgruppen stehen die Anomalien in Korrelation mit der
Tumorgröße und der Überexpression von HMGA Gene.
HMGA2 zeigte in den Myomen mit 12q14~15 Rearrangement eine
Überexpression im Vergleich zu den dazugehörigen Myometrien und
zytogenetisch normalen Tumoren. Die Überexpression von HMGA2 wurde
auch im normalen UL gegenüber Myometrien beobachtet. Dies zeigt, dass die
HMGA2 Überexpression eine besondere Rolle in der Pathogenese der UL
spielt.
Die Expression von HMGA1 erschien in den Myomen mit 6p21 Aberrationen
stärker als in den dazugehörigen Myometrien und normalen UL.
Der Anstieg durchschnittlicher Expression von HMGA1 mRNA in UL mit 6p21
Rearrangierungen war viel weniger stark als der des HMGA2 mRNA bei
12q14~15 Aberrationen.
4Langzeitkulturen der Myomzellen mit unterschiedlichen HMGA Proteingehalt
führten nicht zur Immortalisierung dieser Zellen, auch nicht dann, wenn in den
Zellen mit HMGA2-Überexpresion eine hohe Proliferationsrate vorlag.
Aus den Untersuchungen zur Genomstabilität in UL, konnte keine Korrelation
zwischen HMGA2 Expression und der Zunahme der Instabilität des Genoms
festgestellt werden. Dies legt die Vermutung nahe, dass die Genomstabilität
durch andere Faktoren unterstützt wird, die einer hohen HMGA2-Expression
begleiten.
Weitere Studien sind in diesem Bereich noch zu empfehlen. Hinsichtlich der hohen
Homologie der HMGA2 und HMGA1 Proteinen, scheint eine größere Auswirkung von
HMGA1 auf die Entwicklungen von UL möglich.
Auf jeden Fall sind detailliertere Analysen der HMGA1-Expression und Untersuchung
des Proteingehalts zu empfehlen. Darüber hinaus sind weitere Untersuchungen von
anderen Faktoren notwendig, die eine Rolle beim Zellwachstum spielen und mit
HMGA Proteinen zusammenhängen.
51. Introduction
Uterine leiomyomas (UL) are the most common benign tumors of the female genital
tract. Although progression of leiomyoma to malignant leiomyosarcoma (LMS)
happens very rarely (frequency of <0.1%) (Sandberg, 2005), considering the
frequency and complications of this tumor makes it necessary to do further
investigations into the etiology of the UL. This study concentrates on understanding
of the pathobiology of the UL based on cellular and molecular analysis of myomas.
The reported prevalence of UL is ranging from 3.3% to as high as 87% (Borgfeldt
and Andolf, 2000; Baird et al., 2003a). They are common in reproductive age (Kane,
2002). The available studies indicate that at least one third of women over 30 years
old have one or more UL (Cramer and Patel, 1990; Baird et al., 2003a; Heinemann et
al., 2003). Myomas are more prevalent in African Americans (16-87%) than in
European American or European women of reproductive age (9-78%), (Marshall et
al., 1997; Chen et al., 2001; Faerstein et al., 2001; Baird et al., 2003a). Furthermore,
African American women are diagnosed at earlier ages. Additionally African
Americans have more severe symptoms, larger in size and greater in number of
tumors than white women (Kjerulff et al., 1996).
Most commonly UL develop within the uterus. However, leiomyomas are also found
in other parts of the body, for example in gastrointestinal tract or within the walls of
vessels (Blake, 2007). Less frequently UL occur in the cervix and in the fallopian
tubes and even less commonly in the broad ligament (Blake, 2007). According to
their location in the uterus, UL are classified into three groups: submucous,
subserous, and intramural (Kane, 2002). Submucous myomas are located
immediately beneath the endometrial or decidual surface of the uterine cavity.
Subserous tumors project out from the peritoneal surface of the uterus while
intramural forms are confined to the myometrium. Submucous and subserous
myomas may at times be attached to the uterus by stalks (pedunculated).
Histopathological analyses reveal that UL are well circumscribed,
pseudoencapsulated, solid and pearly white or lightly tanned round masses with size
usually ranging from 1 mm to >30 cm (Blake, 2007), although a diameter as large as
72 cm was documented too (Kane, 2002). Microscopically UL are showing interlacing
bundles of spindle-shaped or stellate-type smooth-muscle cells with little cellular
6pleomorphism or mitotic activity (<5/10 hpf). The growth pattern of UL shows a low
mitotic activity (Blake, 2007).
Since the majority of tumors are asymptomatic, many remain undiagnosed (Cramer
and Patel, 1990). The most common non-invasive method of diagnosis is
transvaginal ultrasound. The clinical symptoms of UL include excessive menorrhagia,
severe abdominal pain, urinary incontinence, frequent urination, backache, and
constipation (Carlson et al., 1994; Kjerulff et al., 1996; Coronado et al., 2000; Morton,
2000; Ligon and Morton, 2001; Kane, 2002; Wegienka et al., 2003; Sandberg, 2005).
The severity of clinical symptoms depends on the location of the UL within the uterus
(Cotran et al., 1989) and their size and number (Buttram and Reiter, 1981).
Leiomyomas may lead to serious complications e.g. infertility, spontaneous
abortions, premature labor, dystocia or anemia (Carlson et al., 1994; Greenberg and
Kazamel, 1995, Kjerulff et al., 1996; Morton, 2000; Coronado et al., 2000; Kane,
2002; Wegienka et al., 2003).
The etiology of myoma is largely unknown; nevertheless, several risk factors have
been indicated in epidemiologic studies (see Tab. 1.1).
Treatment alternatives include hormonal therapy (anti-estrogen or anti-
progesterone), observation, embolization, myomectomy, or hysterectomy (Kane,
2002). Choice of treatment depends on various factors, including size of tumor,
severity of symptoms, and rate of growth, as well as the woman’s desire to have
children (Buttram and Reiter, 1981).
Many hypotheses have been advanced to explain the etiology of the UL through the
investigation of the hormonal factors, growth factors, genetic factors, and molecular
biology. It has been suggested that an increased level of estrogen and progesterone
lead to an increment of the mitotic rate that may contribute to myoma formation by
increasing the risk of somatic mutations (Rein, 2000). Other hypotheses based on
the findings of significantly increased levels of estrogen receptor in the myometrium
of those who develop myomas suggest a correlation between the pathogenesis of UL
and an inherent abnormality in the myometrium (Richards and Tiltman, 1996).
Furthermore, Dixon et al., (2002) suggested that the most significant contributor to
growth of UL (independent of tumor size and also autonomously for each tumor in a
given patient) is abnormal cell proliferation (Dixon et al., 2002). Others have
suggested a predisposing genetic factor for UL on the basis of its familial and ethnic
7predominance (Marshall et al., 1997; Schwartz et al. 2000a; Van Voorhis et al., 2002;
Okolo et al., 2005; Uimari et al., 2006).
Tab.1.1: Potential risk factors associated with uterine leiomyoma.
Characteristic/Factor
Risk
associated
with myoma
References
African American ethnic group ↑ Marshall et al., 1997; Chen et al., 2001; Faerstein et al.,
2001; Baird et al., 2003a
Late reproductive age (>30) ↑ Schwartz, 2001; Wise et al., 2005; Baird, 2005
Early menarche ↑ Schwartz, 2001; Flake et al., 2003
Nulliparity ↑ Myers et al., 2002; Flake et al., 2003; Baird et al., 2003a;Wise et al., 2005
Tamoxifen treatment ↑ Deligdisch, 2000
Pregnancy ↓ Parazzini et al., 1988; Marshall et al., 1998
Multiparity ↓ Kjerulff et al., 1996; Parazzini et al., 1996; Luoto et al.,2000; Myers et al., 2002
Menopause ↑↓ Schwartz, 2001; Palomba et al., 2002; Flake et al., 2003
Oral contraceptive ↑↓
Ross et al., 1986; Parazzini et al., 1988; Marshall et al.,
1998; Schwartz, 2001; Faerstein et al., 2001; Myers et al.,
2002; Flake et al., 2003; Wise et al., 2004
BMI ↑↓
Parazzini et al., 1988; Marshall et al., 1998; Luoto et al.,
2000; Schwartz, 2001; Myers et al., 2002; Flake et al., 2003;
Brett and Higgins, 2003
Hypertension ↑↓ Schwartz, 2001; Palomba et al., 2002; Flake et al., 2003
Smoking ↑↓ Ross et al., 1986; Cramer et al., 1995; Marshall et al., 1998;
Schwartz, 2001; Faerstein et al., 2001; Wise et al., 2004
Diet ↑↓ Woods et al., 1996; Chiaffarino et al., 1999
Abortion ↑↓ Parazzini et al., 1996,1988
Perineal talc use ↑↓ Parazzini et al., 1988; Marshall et al., 1998; Faerstein et al.,
2001
History of pelvic inflammatory
disease
↑↓ Parazzini et al., 1988; Marshall et al., 1998; Faerstein et al.,
2001
Chlamydial infection ↑↓ Parazzini et al., 1988; Marshall et al., 1998; Faerstein et al.,
2001
Use of intrauterine device ↑↓ Parazzini et al., 1988; Marshall et al., 1998; Faerstein et al.,2001
↑: increased probability of UL, ↓: decreased probability of UL, ↑↓: inversely associated with myoma in
different studies.
8The possibility of genetic predisposition to fibroids remains an unanswered question.
So far the issue of genetic predisposition has been investigated from four
perspectives: twin studies, familial aggregation, ethnic predisposition, and
association with an inherited syndrome (Winkler and Hoffmann, 1938, Thyresson and
Su, 1981; Kurbanova et al., 1989; Treloar et al., 1992; Vikhlyaeva et al., 1995;
Marshall et al., 1997; Baird et al. 1998; Luoto et al., 2000; Schwartz et al. 2000a,b,
Chen et al., 2001; Faerstein et al., 2001; Gross and Morton, 2001; Baird et al.,
2003a). The available studies on the genetic predisposition show higher correlation
for hysterectomy in monozygotic than dizygotic twins (Treloar et al., 1992, Luoto et
al., 2000), although, by ultrasound examination the risk ratio for fibroids in a
monozygous twin whose sister had been diagnosed with fibroids was the same as for
a dizygous twin (Luoto et al., 2000). That could be because of low participation rate
(Flake et al., 2003); higher occurrence of myomas in first-degree relatives of women
with UL than those without (Winkler and Hoffmann 1938, Kurbanova et al. 1989,
Vikhlyaeva et al., 1995, Schwartz et al. 2000a); higher prevalence among African
American women than other ethnic groups and also higher clinical prevalence
because of a higher frequency of multiple lesions and greater size of the fibroids
(Marshall et al., 1997; Baird et al. 1998; Chen et al., 2001; Faerstein et al., 2001;
Baird et al., 2003a); and existence of a family histories in Reed’s Syndrome or
multiple leiomyomata in the skin, uterus, or both (Fisher and Helwig 1963; Reed et al.
1973; Thyresson and Su, 1981).
There is a general acceptance in the literature that UL are monoclonal. Studies
supporting this acceptance have been based on the Lyon hypothesis that only one X
chromosome is active in every female cell. Thus, some studies of clonality used the
X-linked glucose 6- phosphate dehydrogenase (G6PD) isoenzymes (Linder and
Gartler, 1965; Townsend et al., 1970). Other studies analyzed the existence of both
G6PD types (A and B) in almost all myometrium samples in contrast to only one
G6PD type in each of UL, also identifying both tumors in the same patient. Further
investigations to discriminate between active and inactive alleles of X-linked genes
have used the X-linked androgen receptor gene (Mashal et al., 1994) and the X-
linked phosphoglycerokinase gene (Hashimoto et al., 1995).
As for genetic conditions of UL at least four major cytogenetic subgroups have been
described:
9At least one-half of UL appears to be cytogenetically normal. Abnormality in the
cytogenetic of UL is reported in a range of 7% to 46% (Nilbert et al., 1990, Vanni et
al., 1991, Kiechle-Schwarz et al., 1991, Pandis et al., 1991, Meloni et al., 1992, Rein
et al., 1998, Brosens et al., 1998, Hennig, 1999, Kataokaa et al., 2003).
One of the most common abnormalities is a particular rearrangement of the long arm
of chromosome 12 i.e. a translocation between chromosomes 12 and 14, usually as
a t(12;14)(q14~q15;q23~q24), with a frequency of 17-46% of karyotypically abnormal
UL (Nilbert and Heim, 1990; Hennig, 1999; Ligon and Morton, 2000). This
abnormality is of particular interest because the same region of 12q is also commonly
rearranged in a variety of other mesenchymal solid tumors e.g. lipomas, breast
fibroadenomas, endometrial polyps, pulmonary chondroid hamartomas (PCH),
hemangiopericytomas, angiomyxomas (Turc-Carel et al., 1986; Bullerdiek et al.,
1997; Calabrese et al., 1991; Mandahl et al., 1993; Vanni et al., 1993; Ozisik et al.,
1994; Dal Cin et al., 1995; Fletcher et al., 1995). The critical gene that located in the
chromosome 12q14~q15 region is HMGA2 (Ashar et al., 1995; Schoenmakers et al.,
1995). The HMGA2 expression has been detected in UL with 12q14~15
rearrangements, but not in matched normal myometrium (Gattas et al. 1999). In
addition, the 14q23~q24 region is also involved in several mesenchymal benign
tumors, including uterine leiomyomas, pulmonary chondroid hamartomas, and
endometrial polyps (Walter et al., 1989; Nilbert and Heim, 1990; Rein et al., 1991;
Dal Cin et al., 1993, 1995; Fletcher et al., 1995; Vanni et al., 1995; Kazmierczak et
al., 1995, 1996). Two candidate genes in this region of chromosome 14 are ESR2
(Estrogen Receptor Beta Gene) (Pedeutour et al., 1998) and RAD51L1 (a member of
the RAD51 recombination repair gene family) (Albala et al., 1997; Schoenmakers et
al., 1999).
Deletions of the long arm of chromosome 7 are present in some studies as the most
frequent abnormality in UL (Nilbert and Heim, 1990; Pandis et al., 1991; Meloni et al.,
1992) and by the others as the second most common rearrangement in this tumor
(Rein et al., 1991; Vanni et al., 1991; Ligon and Morton, 2000). del(7)(q22q32) is
present in about 17-24% of karyotypically abnormal UL (Nilbert and Heim, 1990;
Hennig, 1999; Ligon and Morton, 2000).
Another cytogenetic subgroup is characterized by aberration of 6p21, where the gene
for another member of HMGA family, HMGA1 is located (Friedmann et al., 1993).
Rearrangements include deletions, inversions, translocations, and insertions,
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occurring with a frequency of <5-13% (Nilbert and Heim, 1990; Hennig, 1999; Ligon
and Morton, 2000). In a small series of UL, Tallini et al. (2000) were able to show that
rearrangements of 6p21 leads to an overexpression of HMGA1. However, quantifying
the expression of HMGA1 mRNA in UL of this subtype was not performed.
Trisomy 12 as another cytogenetic subgroup was reported in as many as 2-12% of
karyotypically abnormal UL (Nilbert and Heim, 1990; Hennig, 1999).
Other cytogenetic abnormalities have been reported in UL as well, but with lower
frequency. Among these are cases of structural rearrangements involving
chromosome 1 particularly in the form of ring chromosomes, also translocations and
deletions (Nilbert et al., 1988; Casartelli et al., 1989; Vanni et al., 1989; Havel et al.,
1989; Mark et al., 1989), aberrations of the X chromosome preferentially involving
Xp11~p22 (Turc-Carel et al., 1988; Vanni et al., 1989; Fan et al., 1990; Mark et al.,
1990; Nilbert and Heim, 1990; Ozisik et al., 1992), rearrangements of chromosome
10 including deletions affecting the long arm of chromosome 10 (especially band
q22) as well as monosomy 10, and rearrangements of chromosome 3 (Nilbert et al.,
1990).
Some studies suggest that the chromosomal rearrangements are in fact secondary
events during the development of UL. The secondary nature of the chromosomal
rearrangements is supported by the findings suggesting that mosaic karyotype
(normal/aberrant) myomas are of the monoclonal origin (Mashal et al., 1994); mosaic
karyotype myomas (normal/aberrant) are significantly smaller in size than those
solely composed of abnormal cells (Rein et al., 1998).
A correlation between chromosomal anomalies and the size of tumors was found.
The mean diameter of myoma among specimens with abnormal (non-mosaic)
karyotypes was significantly greater than myomas with normal karyotypes (Rein et
al., 1998). In addition, Hennig et al. concluded that it is true for myomas with
12q14~15 changes but not for the groups of tumors characterized by deletion of
chromosome 7 (Hennig et al., 1999). Brosens et al. (1998) showed a positive
relationship between the presence of a cytogenetic abnormality and the anatomic
location of a tumor. Submucous myomas had significantly fewer clonal abnormalities
(12%) than subserosal (29%) or intramural myomas (35%).
HMGA genes are involved in two major subgroups of karyotypically abnormal UL.
HMGA1 (formerly known as HMGI(Y)) is located at chromosomal band 6p21 (in 6p
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aberrant group) and HMGA2 (formerly known as HMGI-C) is located at chromosomal
band 12q14~15 (in 12q14~15 aberrant group).
The high mobility group (HMG) proteins are architectural components affecting the
structure and activity of the chromatin because of their ability to bind it (Grosschedl et
al., 1994). The higher levels of HMG proteins cause irregular expression of different
genes, thus inducing developmental abnormalities. Therefore, HMG proteins are the
underlying reason of many diseases and tumorigenesis e.g. due to their up-
regulation of CCNB2 gene by HMGAs in pituitary adenomas (De Martino et al.,
2009), inhibition of nucleotide excision repair in breast cancer cells (Adair et al.,
2005), or induction of type 2 diabetes, due to an HMGA-dependent downregulation of
the insulin receptor (Foti et al., 2005).
HMGA (AT-hooks) proteins which are present in stem cells and casually linked to
their self-renewal ability are: able to bind to the minor groove of AT-rich stretches in
DNA with three DNA-binding domains; induce conformational changes in chromatin
structure and enable the regulation of the expression of various target genes. They
can also interact with other proteins by means of acidic C-terminal tail (Fusco and
Fedele, 2007). HMGAs are found abundant in undifferentiated and proliferating cells
of early embryos and undetectable in fully differentiated cells. In particular,
expression of HMGA2 mRNA has not been detected in any of the several adult
tissues tested by RT-PCR (Rogalla et al., 1996) with one interesting exception:
expression of HMGA2 during spermatogenesis in testis, at least in mice (Chieffi et
al., 2002). Conversely, HMGA1 is expressed at very low constant levels in normal
adult tissues (Chiappetta et al., 1996).
These chromatin binding proteins regulate key signalling pathways in cell
proliferation or apoptosis (Sgarra et al., 2004; Hoyos et al., 2004; Fedele et al.,
2005). HMGA2 is established as a regulator of human genes linked to human
embryonic stem cell growth, mesenchymal cell differentiation and adipogenesis (Li et
al., 2007). This protein (HMGA2) is also involved in epithelial-mesenchymal transition
by employment of TGF-β (Thuault et al., 2006). Narita et al. (2006) introduced a
novel role for HMGA proteins - which are also active in tumor suppressor networks
by having a role in cellular senescence and heterochromatin formation. In other
independent studies HMGA2 was also identified as a target for the let-7 family of
microRNAs (Shi et al., 2009; Rahman et al., 2009; Guoying et al., 2009). The findings
based on the analysis of the tumor cell proliferation and cell transformation,
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repression of HMGA2 following the disruption of let-7 (Lee and Dutta, 2007; Mayr et
al., 2007) support again the oncogenic role of HMGA2.
A decrease of HMGA2 has been recently linked to self-renewal of hematopoietic as
well as neural stem cells (Nishino et al., 2008). Overexpression of HMGA directly
induce a faulty expression of many genes in different benign and malign human
tumors e.g. up-regulation of MMP-2 (Matrix Metalloproteinase-2) gene by HMGA1 in
large-cell lung cancer (Hillion et al., 2009).
Other recent studies have linked HMGA proteins with an increased genomic
instability due to a reduced capacity to repair DNA damage. Inhibition of nucleotide
excision repair by HMGA1 (Adair et al., 2005) and suppression of nonhomologous
end joining (NHEJ) repair by overexpression of HMGA2 (Li et al., 2009) are reported
as the pathways leading to increased DNA instability. Li et al., (2009) analyzed the
cytogenetic stability of fibroblasts transfected by a construct encoding HMGA2 as a
hallmark of deficient NHEJ. They introduced HMGA2 as a regulator of NHEJ that
impairs DNA-PK dynamics by altering Ku (a heterodimer with DNA end binding
activity and necessary for proper DSB repairing by NHEJ (Moore et al., 2005))
binding to DNA ends. On the basis of this analysis Li et al. argued that this regulator,
as an inhibitor of NHEJ through reduction of DNA stability, facilitates the
accumulation of chromosomal aberrations, a central feature of tumorigenesis.
At the same time, HMGA2 is a protein abundantly expressed during embryonic and
fetal life (Rogalla et al., 1996; Li et al., 2007) and it is unlikely that this protein per se
destabilizes the genome. Therefore, Bullerdiek and Rommel (2010) proposed that in
this context a plausible assumption is that the cytogenetically unstable cells,
displaying sporadic translocations or dicentrics, are those with strong overexpression
of the recombinant HMGA2 in a range usually not found during embryonic
development.
Depending on further parameters as e.g. the cell type affected, aneuploidy is
believed to cause cancer potentially (Boveri, 1902, 1914; Pellman, 2007). However,
Weaver et al., 2007 suggested that an increased rate of this common characteristic
of cancer cells can be a more effective inhibitor (depending on the level of genomic
damage that is induced) than initiator of tumorigenesis (Weaver et al., 2006).
Thus, for biosafety studies cytogenetic analyses are a valuable tool to check the
genomic stability of stem cells and their possible malignant transformation. In this
field Izadpanah et al. (2008) have described changes during long-term in vitro
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expansion of adult stem cells of human and rhesus origin. This study has reported
that: (1) bone marrow and adipose tissues derived stem cells of human origin had
diploid chromosome numbers throughout all passages analyzed; (2) an increasing
percentage of tetraploid metaphases was reported for the rhesus bone marrow stem
cells and (3) aneuploid cells characterized by random loss of chromosomes are
described. As a result it was concluded that these cell populations had lost their
ability to maintain chromosome stability during further cell divisions. However, in
relation to the genomic instability these results should be interpreted with caution.
The reason for concern is based on the consideration that UL are a naturally
occurring model of tumor which overexpresses HMGA proteins in subsets of cases.
Consequently, tumors with very low expression and those overexpressing either of
the HMGA genes are present.
The purpose of the present study is to contribute to the genetic analysis of the UL
through investigation of the correlation between cytogenetic changes and the
expression of HMGA genes. This study has tested this correlation by the following
steps. First, a large series of UL was classified karyotypically and (tumor-specific)
chromosome aberrations are described. The level of HMGA2 mRNA in a large series
of uterine leiomyomas and HMGA1 mRNA in subgroup 6p21 with a control group of
normal samples was quantified by quantitative RT-PCR. Second, the relationship
between the chromosome aberrations and the relative gene expression of HMGA1
and HMGA2 was analyzed. Finally, considering the HMGA2 expression, and the
existence of single aberrations and chromosome/chromatid breaks, the correlation
between HMGA2 and genome stability was also studied.
14
2. Materials and Methods
2.1. Tissue samples
The samples of uterine leiomyomas (range of size: 0.5 to 20 cm)? analyzed in this
thesis (N=309; 161 patients)? have been collected from patients (age: 24 to 73 years
old) undergoing surgery between May 2006 and December 2009. The samples are
provided by the following Bremen Hospitals: Women’s Clinic, St. Joseph-Stift
Hospital and Department of Obstetrics and Gynecology, DIAKO Evang. Diakonie
Hospital. The UL diagnosis has been confirmed by the histopathological analysis in
all collected samples. Informed consent to conduct scientific research was obtained
from all patients.
In hospital immediately after surgery samples of uterine leiomyomas and
myometrium were snap frozen in liquid nitrogen and stored at -80°C. Another part of
the tumor (in case of UL) was stored in Hank’s solution with antibiotics (200IU/ml
penicillin, 200μg/ml streptomycin) for subsequent analysis of cell culture and
karyotyping. Fixed, paraffin-embedded tissue sections of the tumor (cut into 5μm
sections) have been used for FISH analyses HOPE (Hepes-glutamic acid buffer
mediated Organic solvent Protection Effect).
2.2. Cell culture
2.2.1. Cell culture for primary culture
Following a surgery? samples of primary tumors, for the in vitro culture of leiomyoma
cells, were stored in Hank’s solution. The tumor samples for cell culture were minced
and treated with 4-6 ml 0.26% (200U/ml) collagenase (Serva, Heidelberg, Germany)
and maintained in the incubator with 5% CO2 at 37°C for 5-8 h. Incubation time varied
depending on the texture of the tumors. After centrifugation (1000 rpm for 10 min),
the pellet was resuspended and divided in 2 to 4 culture flasks (50 ml). The cells
were incubated in 5% CO2 at 37°C with culture medium (TC 199 with Earle’s salts
supplemented with 20% fetal bovine serum, 200IU/ml penicillin, 200μg/ml
streptomycin). Based on the daily microscope observations of the proliferation rate of
primary cultures either medium was changed or cells were trypsinised for subculture.
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Regularly, medium was changed two times a week. The first medium change was
performed after adhesion of cells in the bottom of flask, at least two days after the
primary cell culturing.
2.2.2. Subcultivate for monolayer culture
After a good proliferation rate? cell layer filled a bottom flask, a subcultivate with a 1:2
split ratio was made using trypsin (0.05% Trypsin, 0.02% EDTA in PBS). Floating of
cells was controlled by a microscope. The cells were resuspended with 1 ml medium
and subsequently divided into two new same size flasks with 5 ml medium and
incubated at 37°C and 5% CO2.
2.3. Cytogenetic methods
2.3.1. Chromosome preparation
For chromosome analysis of exponentially growing cultures of leiomyoma the
following method was used. Briefly, to arrest cultured cells during mitosis the cells
were incubated in 30 μl colcemid solution (0.06 μg/ml) for 1 hour. Next, the
metaphase chromosome spreads were placed in a hypotonic solution (culture
medium 20%: aqua dH2O = 1:6) for 20 minutes and immediately fixated by the
solution (methanol: acetic acid = 3:1). After three times washing by fixative and
centrifugation the suspension was incubated overnight at 4°C.
2.3.2. Metaphase spread on the objective slides
For metaphases extension the glass slides washed in Ethanol 96% and dH2O and
kept at 4°C were used. Following centrifugation and suction of lotion the suspension
was dropped into cold glass slides. Cells prepared on the glass slide were dried
overnight at 60°C or at 37°C for 2-3 days.
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2.3.3. Staining the chromosomes by G-Banding
The G-band analysis was performed according to the conventional differential
staining technique for the identification of chromosomes and their abnormalities.
Glass slides were treated (for 7 sec.) in the lotion (after 20 minutes incubation at
37°C of 50 ml banding buffer (41% KH2PO4 (1/15 mol) and 59% Na2HPO4 x 2H2O
(1/15 mol) 15 mg Trypsin powder was dissolved and incubated for 9 more minutes),
then transferred immediately to the Giemsa stain (2 ml Giemsa, 5 ml Ethanol 96%,
10 ml Giemsa buffer (50% KH2PO4 (1/15 mol) and 50% Na2HPO4 x 2H2O (1/15
mol)), and 83 ml dH2O.) for 10 minutes and finally washed two times by dH2O before
air drying.
2.3.4. Karyotype analysis
Chromosomes have been captured using fluorescence microscope (Axioplan Zeiss,
Germany). At least 10 (or more in the myomas with a mosaic karyotype) metaphases
were analyzed and 5 of them karyotyped for each case using Macktype 5.5.1
software. The karyotypes were expressed according to the International System for
Human Cytogenetic Nomenclature (ISCN, 2005).
2.3.5 Sample selecting for analysis of genomic stability
From the total sample of the UL, based on cytogenetic analysis, two groups of
myomas have been selected: first, showing aberrations of chromosomal region
12q14~15 and second, with an apparently normal karyotype. In case of single
aberration? only structural aberrations including translocations, deletions, inversions,
insertions and ring chromosomes were considered.
Total number of metaphases for each case and the range of karyotyped metaphases
for each case were considered. The percentage of metaphases including single
aberration or break chromosome/chromatid as well as the percentage of karyotyped
metaphases was analyzed for each group. Student’s t-test (two sided) was used for
the statistical analysis where P values ≤0.05 were considered as significant.
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2.4. Molecular methods
2.4.1. RNA isolation
Total RNA was isolated from fresh-frozen tissue samples using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) as following. Tumor tissues (30- 50 mg; in 600 μl RTL
buffer (Buffer:Bethamercaptanol = 1 ml:10 μl)) were homogenized using 5 mm bead
in a Tissuelyser at 30 Hz for 10 min followed by centrifugation (3 min.) in max speed.
RNA isolation was finalized with DNase treatment in accordance with manufacturer’s
instructions.
Quantification and purity (260/280 nm ratio) of total RNA was determined by
spectrophotometery (3 μl RNA with 70 μl RNase free water). The purity of the RNA
was within a range 1.8 – 2.0. RNA samples were stored at -80°C prior to RT-PCR
analysis.
2.4.2. cDNA synthesis (Reverse Transcription)
Reverse transcription of total 250 ng RNA was carried out with M-MLV reverse
transcriptase and random hexamers (Invitrogen, Karlsruhe, Germany) according to
the manufacturer’s recommendations. Total RNA was transcribed with a blend of 250
ng DNase double digested RNA in a volume of 10 μl with 1 μl random hexamers (150
ng/μl) and 1 μl dNTP-Mix (10mM). RNA was denatured before transcription at 65°C
for 5 min and subsequent cooling on ice for 1 min. After brief centrifugation, 4 μl 5×1st
Strand Buffer, 2 μl DTT (0.1M), 1 μl RNase Out and 1 μl M-MLV Reverse-
Transcriptase (200 U/ μl) were added, then samples were again centrifugated and
incubated in a thermocycler for 10 min at 25°C to allow annealing of the random
hexamers. Reverse transcription was performed at 37°C for 50 min (activation of the
reverse transcriptase and cDNA synthesis) followed by inactivation of reverse
transcriptase (15 min at 70°C).
Controls without enzyme (NoRT) were included for each sample to ensure the
absence of DNA contaminations. cDNA was stored at -20°C.
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2.4.3. Real-time quantitative RT-PCR
Because of different levels of isolated HMGA1 mRNA and HMGA2 mRNA
(transcripted to cDNA)? a relative quantification method with 18S rRNA as
endogenous control was used. 18S rRNA was detected with the following
primer/probe set: forward primer: 5’-GGA TCC ATT GGA GGG CAA AGT-3’, reverse
primer: 5’-AAT ATA CGC TAT TGG AGC TGG AAT TAC-3’, probe: TGC CAG CAG
CCG C.
Quantitative real-time RT-PCR amplification to detect HMGA2 was performed on a
7300 Real-Time PCR System (Applied Biosystems, Darmstadt, Germany) with
TaqMan Universal Mastermix and Assay (No. Hs00171569_m1)? The HMGA2-
specific primers in this assay are spanning the boundary between Exons 1 and 2
(forward primer: 5’- GGA CTT GCA CGA CTA A -3’, reverse primer: 5’- CCG TAC
GTC AAT TGA C -3’). For full-length transcripts of HMGA1 including HMGA1a and
HMGA1b)? a set of primers and probe was designed (forward primer: 5’-GGA CCA
AAG GGA AGC AAA AA-3’, reverse primer: 5’-TTC CTG GAG TTG TGG TGG TTT -
3’, probe: 6-FAM-AAG GGT GCT GCC AAG ACC CGG-MGB). The probes were
diluted in 1:10 concentration for expression of 18S rRNA. Of each cDNA, 2 μl served
as template in a final reaction volume of 20 μl. The actual Real- Time PCR was
carried out in the following schema:
For HMGA1 and 18S rRNA;
Taqman Universal PCR Master Mix 10 μl
Forward- Primer 1.2 μl
Reverse- Primer 1.2 μl
Probe 0.2 μl
H2O 5.4 μl
cDNA 2.0 μl
Total volume 20 μl
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For HMGA2;
Taqman Universal PCR Master Mix 10 μl
Assay (Include primers and probe) 1.0 μl
H2O 7.0 μl
cDNA 2.0 μl
Total volume 20 μl
In order to control and reduce failures, all reactions were run in triplicate. For each
run? nontemplate controls (NTC) and reactions without reverse transcriptase (-RT)
were included. Reaction condition was as follows: 2 min at 50 °C, 10 min at 95 °C,
and 50 cycles of 15 sec at 95 °C and 1 min at 60 °C.
2.5. Fluorescence in situ hybridization
FISH analysis on metaphase preparations was performed after GTG banding of the
metaphase spreads.
For determination of rearrangements involving 6p21 and HMGA1, respectively,
fluorescence in situ hybridization (FISH) was performed on metaphase preparations
of the cases with karyotypically 6p rearrangements and myomas with a high
expression of HMGA1 with or without such rearrangements, and also some normal
cases as a control.
For FISH, two overlapping clones CTD-2522J1 (GenBank accession numbers
AQ280064 and AQ280066) and CTD-2510D13 (GenBank accession number
AQ264849 and AQ264850), both located distal to HMGA1 in 6p21, and two
overlapping clones CTD-2524P4 (GenBank accession number AQ310763 and
AQ277896) and RP11-140K17 (GenBank accession number AQ385566 and
AQ385568), both located proximal to HMGA1, in 6p21 were used.
From the results, colocalized signals (green/red) indicate a nonrearranged breakpoint
region, whereas separated green and red signals indicate a rearrangement of the
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chromosomal region 6p21 and HMGA1, respectively. Details were described before
(Hashemi Nezhad et al., 2010).
For FISH analysis aimed to finding HMGA2 rearrangement, three BAC clones were
used as break-apart probes. RP11-745O10 (AC078927) and RP11-293H23
(AC012264) are located distal (3‘) to HMGA2. RP11-269K4 (AQ478964 and
AZ516203) is located proximal (5‘) to HMGA2. Labeling was performed by nick
translation (Roche Diagnostics, Mannheim, Germany) either with digoxigenin (RP-
269K4) or biotin (RP11-745O10 and RP11-293H23). For interphase FISH, formalin-
fixed, paraffin-embedded (FFPE) tissue sections were used.
For analysis of the results of interphase FISH, nuclei with two colocalized red/green
signals (RG) were scored as normal. Nuclei with one colocalized red/green signal,
one single red, and one single green signal (1RG1R1G) were scored as positive for
HMGA2 rearrangement. The details were described before (Klemke et al., 2009).
2.6. Statistical methods (Analysis of gene expression)
The relative expression was calculated by the ∆Ct method, using 18S rRNA as
endogenous control and by calibrating the HMGA1 and HMGA2 expression of a
myometrial sample matching to a normal myoma. The significance of differential
HMGA1 and HMGA2 expression between the various groups of myomas
(myometrium, myomas with and without 6p21 aberrations in case of HMGA1 and
myomas with and without 12q14~15 aberration in case of HMGA2) was determined
by the Student’s t-test.
Here, it should be acknowledged that a part of laboratory work was done by Mrs
Mahboobeh Tadayyon as her master thesis; the cytogenetic analysis of 56 UL
including myomas undergoing long-term cultur, also RNA isolation and PCR of some
samples.
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3. Results
3.1. Overexpression of HMGA2 in uterine leiomyomas points to its
general role for the pathogenesis of the disease
Klemke et al., 2009
High-mobility group protein A2 was reported to be detected in different benign
tumors, as well as some malignancy. The role of HMGA2 protein in the initiation and
development of tumors was discussed. Due to the frequency of existence of this
protein and high incidence of UL, a large series of myomas (n=180) including tumors
with 12q 14~15 rearrangements (n=13), UL with a cytogenetically normal karyotype
and matching myometrial tissues (n=51) were analysed by quantitative real-time
reverse-transcription polymerase chain reaction.
The highest expression levels for HMGA2 were observed in UL with rearrangements
affecting the chromosomal region 12q14~15 and that was expressed at lower levels
in UL without such aberrations. However, the comparison between the expression in
myomas and matching myometrial tissues indicated significant (P<0.05)
overexpression of HMGA2 also in the group of fibroids without 12q14~15
rearrangements. This general upregulation of HMGA2 regardless of the presence or
absence of such chromosomal abnormalities suggests a general role of HMGA2 in
the development of the disease.
3.2. Loss of let-7 binding sites resulting from truncations of the 3’
untranslated region of HMGA2 mRNA in uterine leiomyomas
Klemke et al., 2010
It was found, that the rearrangements of chromosomal segment 12q14~15, where it
encodes the high mobility group At-hook 2 (known as the major subgroup of
cytogenetic abnormal UL), leads to an overexpression of HMGA2. Therefore, the
regulation of this gene is also considerable in the investigation of molecular
mechanisms causing an overexpression, especially in those tumors with
cytogenetically detectable rearrangements with breakpoints in - or close to 12q14~15
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region. MicroRNAs of the let-7 family are identified as post-transcriptional regulators
of HMGA2. In a variety of mesenchymal tumors (e.g., leiomyomas, lipomas , and
pulmonary chondroid hamartomas) (Ashar et al., 1995; Schoenmakers et al., 1995;
Kazmierczac et al., 1996; Wanschura et al., 1996), it is observed that HMGA2 was
targeted by breakpoints situated either intragenically or extragenically 3’ or 5’ of the
gene.
It is presumed that intragenic chromosomal breakpoints might cause truncated
HMGA2 transcripts lacking the part of the 3’ UTR, where the let-7 complementary
sites (LCS) are located. Therefore this corresponding loss of LCS would stabilize
HMGA2 mRNA by reduction the sensitivity of the transcript against microRNAs of the
let-7 family and finally leads to a higher protein levels in the cells.
So in this study 13 UL with 12q14~15 rearrangements were checked for truncated
HMGA2 transcripts by real-time reverse-transcription polymerase chain reaction.
From the total of 13 UL eight leiomyomas with such aberrations, the presence of the
complete 3’ UTR with all LCS was detected. Five myomas revealed a differential
expression of exons 1-2 and 3’ UTR with highly reduced 3’ untranslated region levels
in two of which full-length transcripts were almost undetectable.
Results show that approximately one third of UL, bearing targeted HMGA2 locus
affected with chromosomal rearrangements, displayed truncated transcripts. This
gives rise to a higher stability of its transcripts and therefore promotes the
overexpression of protein. Thus, in most of UL, a loss of let-7 complementary sites is
not always responsible for the overexpression of HMGA2; however, it can increase
the effects of a transcriptional de-regulation of HMGA2 in a quite small setting of
these tumors.
3.3. HMGA2 and the p19Arf-TP53-CDKN1A axis: A delicate balance in the
growth of uterine leiomyomas
Markowski et al., 2010
Uterine Leiomyomas (UL) are defined to happen through a monoclonal abnormal
proliferation of myometrial cells. One of the regular phenomena which exists in
premalignant lesions and induces a growth cease especially by two potent growth-
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inhibitory pathways as represented by p16Ink4a and p19Arf is the oncogene-induced
senescence (OIS). Although there has not been any evidence of relevance between
OIS and the development of UL discussed yet, HMGA2 as a major target gene of
recurrent chromosomal abnormalities in UL has been related directly with the
repression of the Ink4a/Arf (CDKN2A) locus. Taking this point into consideration, this
study investigated the probable contribution of HMGA2 to the development of
leiomyomas through repressing this locus. The result was contradictory. It was
observed that UL typically exhibits higher levels of p19Arf mRNA comparing to
myometrium, and likewise there could be seen a higher level of UL with 12q14 15
rearrangements rather than UL with other cytogenetic aberrations. Moreover, it was
found that the existence of a significant correlation between the expressions of p19Arf
and CDKN1A activates senescence rather than apoptosis in UL. Notably, the size of
tumors was also correlated with the levels of HMGA2, p19Arf, and CDKN1A. This
shows that the p19Arf pathway counteracts with enhancing the growth potential. It can
be presumed that the UL probably performs a program already present in their
original cell, and when activated, protects the genome, for which the enhanced
proliferation can be named as an example. The research concluded that, based on
the results, the p19Arf-TP53-CDKN1A pathway plays an important role in controlling
the growth and genomic stability of uterine fibroids.
3.4. 6p21 rearrangements in uterine leiomyomas targeting HMGA1
Hashemi Nezhad et al., 2010
HMGA2 as targeting gene in the most frequent cytogenetic abnormal subgroup of UL
is discussed in the initiation and development of myomas in different studies. HMGA1
is another member of high-mobility group protein A which is targeted in another non-
random aberrant subgroup of UL with 6p21 rearrangements. An overexpression of
HMGA1 was detected before resulting from such rearrangements in the locus of the
gene in the short arm of chromosome 6 (Sornberger et al., 1999; Tallini et al., 2000).
However, it seems that yet no study quantifying the expression of HMGA1 mRNA in
UL of this subtype has been performed. Thus, aimed to quantify the expression of
HMGA1 mRNA in UL, the expression of HMGA1 was analyzed in a series including
tumors with 6p chromosomal aberrations (n=7) and cytogenetically normal tumors
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(n=8) as a control group by quantitative real-time reverse-transcription polymerase
chain reaction. The average expression level in the 6p21 group was found to be 5.6
times higher than that in the control group and with one exception all cases with 6p21
alteration revealed a high expression of HMGA1 mRNA than cytogenetically normal
tumors. However, what distinguishes the tumors of both types is the level of
overexpression of HMGA genes compared to myometrium. Nevertheless, the
increase of the average expression of HMGA1 mRNA in these cases was
significantly less strong than that of HMGA2 mRNA in case of 12q14~15 aberrations
identified in the previous studies.
3.5. 12q14~15 aberrations do not enhance the chromosomal instability in
uterine fibroids
Hashemi Nezhad et al., submitted
Resuming the previous study of high-mobility group protein A and their roles in the
development of tumors, this time genome stability in the UL and its correlation with
HMGA2 expression was considered and investigated as a possible role for HMGA2
protein. For this aim, three groups of myomas have been selected based on
cytogenetic analysis. The first one showed the rearrangements of chromosomal
region 12q14~15 (with a high expression of HMGA2) without single aberration or
chromosome/chromatid break (N=16); the second one, an apparently normal
karyotype without single aberration or chromosome/chromatid break (N=151) as the
cells with low levels of HMGA2 considered as the control group? and the third, all UL
affected with single aberration or chromosome/chromatid break (N=46) as cases with
higher genome instability. In case of single aberration only structural aberrations
including translocations, deletions, inversions, insertions?and ring chromosomes were
considered.
Total number of metaphases for each case and the range of karyotyped metaphases
for each case were considered. The percentage of metaphases including single
aberration or break chromosome/chromatid as well as the percentage of karyotyped
metaphases was analysed for each group.
From a total of 46 affected UL, 31 samples showed only one impression of single
aberration or break and 15 UL showed more than one (2-4). In most analyzed
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samples, the affected metaphases included one chrb/chtb or single aberration.
However, in 5 myomas two alterations occurred in the same metaphase. In 4 of
these 5 UL two chtb or chrb were observed together. And just in one case (Myoma
659.2, with 4 different occurrence including translocation, two different ring
chromosomes and chrb), r(13) and chrb(15) took place together in the same
metaphase (Fig. 3.9). In comparison between all UL with 12q14~15 rearrangements
and all normal myomas there was no significant difference between the percentage
of impression with a single structural aberration or chromosome/chromatid break.
Concerning the gene expression, there was no significant difference between UL
without single aberration or chrb/chtb and targeted UL with single aberration or
chrb/chtb. Likewise, the expression of HMGA2 was analyzed between affected UL
with just one event and myomas including more than one chrb/chtb or single
aberration as more instable cells. Results confirm that there was no difference
between these two groups of affected UL.
In order to investigate the role of HMGA2 in the stability of genome, these two groups
of myoma cells (normal group and 12q14~15 group) were compared with malignant
cells, as well with higher level of HMGA2 in comparison with normal cells.
Concerning the genome stability, contrary to normal cells that have good and high
stability, the malignant cells are known to have higher genome instability.
If HMGA2 would be considered as a positive factor in induction of genome instability,
it is expected that malignant cells show a far higher expression of HMGA2 than
benign and stem cells, and likewise, these cells should have a high instability in their
genome. However it is proved that malignant cells express the HMGA2 in a lower
level than benign tumors including 12q14~15 rearrangements. It is true that in stem
cells, this group has a high expression of HMGA2 despite their high genome stability
too.
It is unlikely that the stem cell chromatin associated protein HMGA2 which can be
found plentifully during embryonic life (Rogalla et al., 1996; Li et al., 2007), impairs
the integrity and stability of genome. Especially in the phase of the embryonic life, the
strong proliferative activity should happen simultaneous with a proper supply of
genetic integrity. Therefore, it seems plausible to assume that the cells having
12q14~15 abnormalities make a protection for genome in spite of their high HMGA2.
This could be due to the existence of other factors which are associated with this
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high HMGA2 that counteract the effect of HMGA2 in the induction of genome
instability, e.g. high expression of p19Arf.
3.6. Unpublished results
3.6.1. Cytogenetic analysis
In this study? 261 UL from 141 patients have been investigated by cellular and
molecular analysis. The age of patients ranged between 24-80 years old, where age
group between 40 and 50 was the largest (Fig. 3.1).
Fig. 3.1: Distribution of age in the patients with uterine leiomyomas.
The size of tumor was in a range of 0.5–20 cm (Fig.3.2). Aberrant UL showed never
a size smaller than 1 cm (Fig. 3.4).
Based on the cytogenetic karyotyping, UL were subdivided into two major groups.
The first group includes 76 UL that showed chromosomal aberrations and the second
one, 185 UL with an apparently normal karyotype. 65 patients had at least one tumor
with an aberrant karyotype. The frequency of abnormal karyotypes was 29.1% per
nodule and 46.1% per patients. UL with an abnormal karyotype were further
analysed and subdivided into four major cytogenetic subgroups (12q14~15
rearrangements, del(7q22), 6p21 rearrangements, and trisomy 12) (Fig. 3.3).
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Fig. 3.2: Distribution of the size of tumors in the uterine leiomyomas.
Fig. 3.3: Frequency of major cytogenetic subgroups in uterine leiomyomas.
Aberrant UL were also analyzed for mosaic (aberrant/normal, aberrant/aberrant) or
non-mosaic karyotype (Tab. 3.1). From total of 76 UL with an aberrant karyotype,
46% showed a non-mosaic karyotype and 54% revealed a mosaic karyotype (56.1%
A/N, 24.4% A/A, 12.2% A/A/N, 2.4% A/A/A, and 4.9% with a cp karyotype).
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Tab. 3.1: Karyotype and clinical data of all aberrant UL. Karyotypes belong to primary material or first
chromosome analysis and include also the structural single aberrations and FISH karyotype for some
samples (UL with a high gene expression despite normal karyotype and vice versa).
No
Case
No.
Lab
No.
Size
(cm)
Age
(y)
Karyotype
Non-mosaic
or mosaic:
A/N or A/A
1 501 3 10 48
46,XX[36]. nuc ish(269K4,745O10/293H23)x2(269K4 sep
745O10/293H23x1)[23/100]
N.M
2 503 6 4 40 46,XX,inv(5)(q15q31~33),t(12;14)(q15;q24)[13] N.M
3 513 15 5 42 46,XX,del(7)(q22q31)[3] N.M
4 523.1 25A - 33
45,XX,t(12;14)(q15;q24),der(14)t(12;14)(q15;q24),-22[16]/44,XX,-9,
t(12;14),der(14)t(12;14),der(19)t(9;19),-22[1]
N.M
5 523.2 25B - 33
45,XX,t(12;14)(q15;q24),der(14)t(12;14)(q15;q24),-22[15]. Ish
t(12;14)(269K4+,745O10/293H23-;269K4+,745O10/293H23+),
der(14)t(12;14)(269K4+,745O10/293H23+)[11/11]
N.M
6 524 26 - 40 46,XX,del(7)(q22q34) or (q11.2q31)[2] N.M
7 526 32 3 42 45,XX,rob(13;14)(q10;q10)c[15] N.M
8 532.2 34B 5 39 46,XX,inv(1)(p13q32)[16] N.M
9 532.3 34C - 39 46,XX,inv(1)(p13q32)[14] N.M
10 533 35 6 41 46,XX,r(1),t(1;12;14)(p36.3;q14;q24)[19] N.M
11 535.1 37A 5 43 47,XX,+10[2]/46,XX[9] M(A/N)
12 535.2 37B 4 43 46,XX,t(8;11)(p23;q13.1)[6]/47,XX,+12[2]/46,XX[15] M(A/A/N)
13 535.5 37E 3 43 46,XX,del(7)(q11.2?)[2]/46,XX[12] M(A/N)
14 536.1 38A 6 46 46,XX,del(7)(q22q31.2)[13] N.M
15 536.3 38C 3 46 46,XX,del(7)(q21.2q31.2)[6] N.M
16 538.3 40C 6 36 46,XX,ins(2;3)(q32;q22q27)[3] N.M
17 541 43 7 37 46,XX,t(12;14)(q15;q24)[5]/46,XX[9] M(A/N)
18 542.1 44A 7 46 46,XX,inv(7)(p21q22)[3]/46,XX[5] M(A/N)
19 544.2 46B 4 49 46,XX,del(7)(q22q32)[2]/46,XX[4] M(A/N)
20 545 47 5 47 46,XX,t(12;14)(q15;q24)[9]/46,XX[3] M(A/N)
21 546 48 6 45 47,XX,+12[9]/46,XX[3],46,XX,del(7)[1] M(A/N)
22 547.1 49A 2.5 73 46,XX,der(12),der(14)?ins(14;12)[8]/46,idem,r(1)[4] M(A/A)
23 549.4 51D 6 49 48,XX,+der(6),-8,+11,+mar[11] N.M
24 550 53 - 30
46,XX,add(1)(p),der(1)t(1;3?)(q;q),der(3)del(3)(p) or
add(3)(p)t(1;3)(q;q),der(4)t(3;4)(p;q)[17]
N.M
25 551.2 52B 5 45
48,XX,+4,+12[11]/48,XX,+4,del(7)(q22q31.2),+12[8]/48,XX,t(1;3),
+4,+12[1]/48,XX,t(2;8),+4,del(7),+12[1]/47,XX,del(7)+12[1]
M(A/A)
26 552.2 54B 10 49
46,XX,t(2;12)(q33;q13)[17]. ish t(2;12)(745O10/293H23+;269K4-)
[4/4]
N.M
27 554.2 56B 2.0 41 46,XX,del(13)(q13or14q31)[7]/46,XX[9]/47,XX,+12[1] M(A/N)
28 556 57 5 42
46,XX,t(3;5;12)(q23~25;p13~15;q13~15)[11]/45,XX,t(3;5;12)
(q23~25;p13~15;q13~15),-22[10]
M(A/A)
29
No
Case
No.
Lab
No.
Size
(cm)
Age
(y)
Karyotype
Non-mosaic
or mosaic:
A/N or A/A
29 559.2 61B 10 73 46,XX,der(7)del(7)(q11.2q31)inv(7)(q11.2q36)[16]/46,XX[2] M(A/N)
30 564.2 67B 3 65
46,XX,del(7)(q21.2q31.2)[12]/46,XX,t(1;3)(q25;q26),del(7)
(q21.2q31.2)[4]
M(A/A)
31 573 76 5 37
46,X,t(X;2)(p11.4;p25),del(7)(q11.2q22),inv(9)(p11q13)c[10]/46,XX,
inv(9)(p11q13)c[11]/46,XX,del(7)(q11.2q22),inv(9)(p11q13)c[1]
M(A/A)
32 576.5 79E 6 49
46,XX,del(7)(q22q32),r(16)(pterqter)[5]/46,XX[8]/46,XX,del(7),+12,
-16[1]
M(A/N)
33 579 82 1.5 49 46,XX,t(12;15;14)(q15;q26;q24)[20]/46,XX[1] N.M
34 580 83 8 40
46,XX,der(7)del(7)(p)del(7)(q),t(12;14)(q15;q24)[3]/46,XX,idem,der(
8)add(8)(q),der(10)add(10)(q)[16],45,XX,del(7)(q32),t(12;14),-19 [1]
M(A/A)
35 584 87 - 63
46,XX,t(6;14)(p23;q24)[6]/46,XX,t(6;14)(p23;q24),tas(14;21)(pter;qte
r)[11]/46,XX[2]/47,XX,+12[1]
M(A/A/N)
36 591.2 94B 2.5 47 46,XX,del(7)(q22q32)[9]/46,XX[1] N.M
37 593 96 1 44 47,XX,+12[3]/46,XX[15] M(A/N)
38 595.1 98A 3 50 46,XX,del(7)(q22q32)[3]/46,XX[5]/47,XX,+X[1] M(A/N)
39 596 99 12 49 46,XX,ins(2;12)(q34 or q35;q24.3 or q24.1q13),inv(4)(q27q31.3)[22] N.M
40 597.2 100B - 37 46,XX,del(7)(q11.2q21)[15] N.M
41 601 104 5 40 45,XX,del(1)(p3?),-16[4]/46,XX[11] M(A/N)
42 603.2 106B 3 35 46,XX,del(7)(q?)[8] N.M
43 607 110 4 44
44,XX,der(1)t(1;?),der(3),der(5)t(5;?),-6,der(11)?t(11;15)(q25;q22)
,del(15)(q22),der(15)t(15;?),-19[25]. ish der(6)?t(6;?)(CTD-
2524P4+,RP11-140K17+),der(?)?t(6;?)(CTD-2522J1+,CTD-
2510D13+)[13/13]
N.M
44 608 111 5 46 46,XX,ins(8;1)(q12;p22p13)[22] N.M
45 609 112 4 33 46,XX,der(3)t(3?;6)(p23;q?),der(6)(q),der(8)(p)[13]/46,XX[4] M(A/N)
46 610.3 113C 3.5 53 46,XX,t(6;10)(p23;q23)[5]/46,XX[7] M(A/N)
47 612 115 6 44
46,XX,der(1)r(1;?),t(12;14)(q15;q24)[4]/46,XX,t(12;14)(q15;q24)[13]/
45,XX,r(1),t(12;14),der(15)t(15;18),-18[1]/42,XX,der(1)r(1;?),-4,
dic(11;?;15),t(12;14)(q15;q24),-15,-15,-20[1]. ish t(12;14)
(269K4+,745O10/293H23-;269K4+,745O10/293H23-)[10/10]
M(A/A)
48 613.4 117D 4.5 39 46,XX,t(6;11)(p23;q21)[4]/46,XX[12] M(A/N)
49 614.1 116A 2 56 46,XX,del(7)(q22q32)[2]/46,XX[21]/46,XX,t(1;1)[1]/46,XX,der(1)[1] M(A/N)
50 615.1 118A 5 47 46,XX,del(6)(q15 or q16)[19] N.M
51 616 119 8 48 45,XX,-22[17] N.M
52 617 120 8 44
46,XX,der(1)del(1)(p22),der(3)?t(1;3)(p22;q?),der(5)del(5),der(12)
t(12;?)(q24.3;?),-14,-20,+mar1+mar2[6]
N.M
53 618.2 121B 3 38
42~46,X,-X[6],-1[19],t(1;8)(p22;q24)[11],der(1)[6],del(3)[3],add(6)
[19],-8[6],der(8)[4],t(9;14)[19],-10[6],-11[6],-13[6],-14[19],-22[15],
+mar1[18],+mar2[18],+mar3[6],+mar[6][cp19]/46,XX[1]. ish t(6;?)
(CTD-2524P4+,RP11-140K17+;CTD-2522J1+,CTD-2510D13+)
[10/10]
CP
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54 621.1 125A 2.5 42
46,XX,t(6;11)(p21;p15)[7]/46,XX[14]. ish t(6;11)(CTD-
2524P4+,RP11-140K17+;CTD-2522J1+,CTD-2510D13+)[5/17]
M(A/N)
55 622 126 1.5 48 46,XX,del(10)(q24 or q25)[11]/46,XX[5] M(A/N)
56 624.1 128A 3 42 46,XX,del(3)(q22~q23)[19] N.M
57 624.2 128B 2.5 42 46,XX,del(3)(q25q27)[15] N.M
58 625.2 129B 6 46
41~46,XX,-1[16],-2[16],dup(7)(q34q11.2)[16],-13[16],-16[6],+r1[10],
+r2[5],+mar1[3],+mar2[2],+mar3[3][cp16]
CP
59 626.1 130A 6 52
46,XX,der(3)t(3;?)(p21;?),del(13)(q12q14),der(16),der(19)t(3;19)
(p21;q13.4)[16]/46,XX[1]
N.M
60 628.1 132A 4 57 46,XX,t(2;4)(q33;q25)[14]/46,XX[1]/46,XX,t(2;4),t(7;9)[1] N.M
61 628.2 132B 1.5 57
46,XX,?ins(12;14)(q15;q31q24)[5]/46,XX[14]/46,XX,?ins(12;14)
(q15;q31q24),der(4)t(4;14)(q;q10),-14,+mar[1]
M(A/N)
62 630 134 8 44
46,XX,der(2)del(2)(p)del(2)(q),der(11)t(2;11;?)(q;p;?)[13]/46,XX,
idem,del(8),-17,+mar[6]/46,XX[3]
M(A/A/N)
63 632 136 4 47
46,XX,t(12;14)(q15;q24)[12]/46,XX,del(4)(q31orq32),der(10)
?t(10;14)(q24;q32),t(12;14)(q15;q24)[9]/45,XX,der(1)?t(1;2),-2,
add(7)(?q36),t(12;14)(q15;q24)[2]
M(A/A/A)
64 635 139 - 59 46,XX,der(10),del(12)(q13 or q14)[18] N.M
65 641.1 149A 6 41
46,XX,r(1),t(5;8)(q35;q21)[6]/46,XX[2]/45,XX,-1,t(5;8)[2]/45,XX,r(1)
,der(5)t(5;8),-8[1]/44,XX,r(1),-3,t(5;8),-21[1]/44,XX,r(1),-3,t(5;8),-14
[1]/41,X,-X,r(1),der(5)t(5;8),-8,-11,-13,-21[1]/45,XX,-21[1]
M(A/A/N)
66 643.2 151B 6 52
46,XX,t(12;14)(q15;q24)[14]. ish 6p21(CTD-2524P4,RP11-
140K17,CTD-2522J1,CTD-2510D13)x2[9/9]
N.M
67 645 153 8 46
45,XX,r(1),der(13;14)(q10;q10)t(12;14)(q15;q24)[20]/44,XX,-1,
der(13;14)(q10;q10)t(12;14)(q15;q24)[6]/44,XX,der(13;14)t(12;14),
-20[1]
M(A/A)
68 646 154 9.5 47
46,XX,t(2;12)(p21;p13)[11]. ish 6p21(CTD-2524P4,RP11-
140K17,CTD-2522J1,CTD-2510D13)x2[17/17]
N.M
69 652 160 1 71
46,XX,del(7)(q21q31)[4]/46,X,t(X;2)(p22.3;q31),del(7)(q21q31)[2]/46
,XX[8]/47,XX,+8[1]
M(A/A/N)
70 654.2 162B 2.5 43 47,XX,+12[4]/46,XX,[12] M(A/N)
71 656.1 164A 1.1 73 46,XX,add(6)(q?13),der(6)t(6;8)(q?13;q13),der(?8)r(?8)[8]/46,XX[6] M(A/N)
72 656.2 164B 2 73
46,XX,add(6)(q?13),der(6)t(6;8)(q?13;q13),der(?8)r(?8)[6]/45,XX,
add(6)(q?13),der(6)t(6;8)(q?13;q13),der(?8)r(?8),dic(9;19)(q34;p13)
[2]/45,X,-X,add(6),der(6),der(?8)[2]/45,XX,add(6),der(6),der(?8),-21
[1]/44,XX,add(6),der(6),-7,der(?8),-18[1]
M(A/A)
73 656.3 164C 2.5 73
46,XX,add(6)(q?13),der(6)t(6;8)(q?13;q13),der(?8)r(?8)[11]/46,XX[1]
/45,XX,add(6),der(6),der(8),12[1]/45,XX,add(6),der(6),der(8),-18
[1]/45,XX,add(6),der(6),der(8),-15[1]/45,XX,add(6),der(6),der(8),-8,
-20[1]/44,XX,-6,der(6),-8[1]/45,XX,dic(2;7),add(6),der(6),der(8)[1]/
44,XX,dic(2;9),add(6),der(6),-8[1]
N.M
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74 656.4 164D 6.5 73
46,XX,add(6)(q?13),der(6)t(6;8)(q?13;q13),der(?8)r(?8)[12]/45,XX,
idem,-10[1]/45,XX,idem,-19[1]/45,XX,idem,-8,-17,-18,-20[1]/43,X,-X,
idem,-13,-21[1]
N.M
75 656.6 164F 8 73
46,XX,add(6)(q?13),der(6)t(6;8)(q?13;q13),der(?8)r(?8)[2]/45,XX,
add(6)(q?13),der(6)t(6;8)(q?13;q13),-8[11]/44,XX,add(6),der(6),
der(?8),-10,-18[1]/44,XX,add(6),der(6),-8,-22[1]/44,XX,add(6),der(6),
-8,-20[1]
M(A/A)
76 658.1 166A 1 47
46,XX,t(6;10)(p21;q22)[13]/46,XX[8]/44,XX,t(6;10)(p21;q22),-14,-20
[1]/44,XX,-7,-20[1]. ish t(6;10)(CTD-2524P4+,RP11-
140K17+;CTD2522J1+,CTD-2510D13+)[7/19]
M(A/N)
Abbreviations: M: Mosaic, N.M: Non-Mosaic, A/N: Aberrant/Normal, A/A: Aberrant/Aberrant, -:
unknown.
Tumor size was analyzed in different cytogenetic subgroups of UL aiming to
investigate significant differences between these groups, as well as, finding the
correlation between the size of tumors and their chromosomal changes. The
correlation between size of tumor and their chromosomal changes in four major
cytogenetic subgroups of UL (normal, 12q14~15 rearrangements, 6p21
rearrangements, and del(7q)) was analyzed. As reported before (Hennig et al.,
1999), UL with 12q14~15 changes were significantly larger in myomas rather than
those belonging to the other groups. However there was no significant difference (P =
0.585) between normal and 6p21 UL. As it is described before, the mosaic karyotype
myomas (normal/aberrant) are significantly smaller in size than those solely
composed of abnormal cells (Rein et al., 1998) (Fig. 3.4).
Most available studies refer to t(12;14) or involvement of 12q14~15 region as most
prevalent subgroup in cytogenetically abnormal UL (for example Gordon et al., 2003;
Ligon and Morton, 2001). However Sreekantaiah et al. (1994) and Pandis et al.
(1991) reported that a partly deletion of the long arm of chromosome 7 was the most
common aberration in UL. The present study also confirmed that 12q14~15
rearrangements were most frequent aberration (27.6%) followed by del(7q) (23.7%)
in myoma (Tab. 3.2).
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Fig. 3.4: A and B. Analysis of tumor size in different cytogenetic subgroups of UL.
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All rearrangements of chromosome region 14q24 were with 12q14~15 changes (14
UL). However rearrangements of 12q14~15 without simultaneous involvement of
14q23-24 have been reported in seven leiomyomas (Tab. 3.1).
Tab. 3.2: Frequency of different aberration in aberrant leiomyomas.
Chromosomal rearrangement
Number of
cases
Percentage of different
aberration in total aberrant
cases (76UL)
12q14~15 rearrangement 21 27.6%
del(7q) 18 23.7%
Chr.14 aberration 15 19.7%
14q24 rearrangement 14 18.4%
Chr.1 aberration 16 21.1%
1p rearrangement 10 13.2%
6p21 rearrangement 8 10.5%
3q rearrangement 7 9.2%
Trisomy 12 5 6.6%
10q rearrangement 5 6.6%
Monosomy 22 4 5.3%
Chr.5 aberration 4 5.3%
Chr.X aberration 3 3.9%
complex karyotype 2 2.6%
Ring chromosome 12 15.8%
From total 76 aberrant UL in the present study, 18 myomas revealed a karyotype
with loss of chromosomal band 7q22 of which seven cases showed the del (7q) as
the sole change. In eight UL this anomaly was present in a mosaic state
accompanied with normal cells, however in three of them other structural aberrations
were observed with del(7). The t(12;14) that is accompanied by del(7q) was present
just in one myoma, the same range for trisomy 12 and a ring chromosome (ring 16).
Interestingly, a translocation of chromosomes X and 2 was observed in two UL with
mosaic karyotype formula of del(7q) and normal cells that are the whole cases
including structural rearrangements of chromosome X in total analyzed UL.
Trisomy of chromosome 12 as one type of non random abnormality in UL was always
observed in mosaic form in the way that an extra chromosome 12 was revealed in
lesser number of cells (Tab. 3.1).
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Another often discussed anomaly in UL, monosomy of chromosome 22, was
observed in five cases. In three of those cases, loss of a chromosome 22 was
accompanied by rearrangement of 12q14~15. One case showed just monosomy 22
and one case had a composite karyotype (Tab. 3.1). In myoma with complex
karyotype formula (myoma 618.2) with different structural and numerical
abnormalities, most cells (15/19 total analyzed cells) revealed loss of one
chromosome 22.
In the present study, from total 76 aberrant UL, 12 (15.8%) myomas showed a ring
chromosome. Five of them had a ring (1) of which four UL showed ring (1) with a
t(12;14). The last one was accompanied with a t(5;8). Five UL revealed a karyotype
with a r(?8) and involvement of chromosomes 6 and 8 with t(6;8). Notable is that all
of these UL were removed from one patient (myoma 656). One myoma (576.5) had a
r(16) that was accompanied with del(7q). Last case (myoma 625.2) with ring
chromosome revealed a complex karyotype with duplication of chromosome 7 and
monosomy of chromosomes 1, 2, 13, and 16 in all cells and two ring chromosomes
as marked chromosomes without any rearrangement in chromosomes 12 and 14.
Present findings showed r(1) as the secondary change after translocation or insertion
of chromosomes 12 and 14 in two tumors. Accompanied by this change in one
myoma, in other cases ring chromosomes were detected in mosaic karyotype with a
normal clone and/or with a clone of cells losing ring one.
Notably, the chromosomes 17 and 18 were never found abnormal (Tab. 3.1).
3.6.2. Molecular analysis
In undertaking molecular analysis, in addition to 12q 14~15 group the expression of
HMGA2 was also analyzed in the cases with trisomy of chromosome 12 (N=5).
Analysis of the expression of HMGA2 showed no significant difference (P=0.268)
between the group of UL with trisomy 12 and normal group (Fig. 3.5). There was also
a significant difference between cells with trisomy of chromosome 12 and 12q 14~15
group.
The expression of HMGA1 mRNA expression was also checked in two cases of 12q
14~15 rearrangements. The average of relative HMGA1 was 29.8 fold in comparison
with normal group (7.2 fold) and 6p21 group (45 fold) (Fig. 3.6).
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Fig. 3.5: The comparison of HMGA2 expression between normal group of UL and myomas with
trisomy 12.
Fig. 3.6: Quantitative HMGA1 and HMGA2 expression in myomas with normal karyotype, 6p21
rearrangements, and 12q14~15 rearrangements.
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3.6.3. Long–term in vitro expansion of myoma cells
Recent papers have linked HMGA proteins with an increased genomic instability due
to a reduced capacity to repair DNA damage. Thus, in order to do a biosafety study
for more investigation of the roles of HMGA proteins, cytogenetic analyses were used
as a valuable tool to check the genomic stability of stem cells. For this aim, four UL
(one myoma with 12q14~15 rearrangement and high expression of HMGA2, one
case with 6p21 rearrangement and overexpression of HMGA1, and in the same time
of culturing each aberrant case? one normal sample as control) were investigated for
the cytogenetic changes during long-term in vitro expansion.
Chromosome analysis of myoma 646 showed a rearrangement of p arm of
chromosome 12 (46,XX,t(2;12)(p21;p13)). At the same time the molecular study of
HMGA2 in a quantitative real time RT-PCR test resulted in a high expression of
HMGA2. Thus, a FISH analysis with HMGA2 probes was performed for this tumor
sample. Metaphase FISH revealed a cryptic insertion of q15 of chromosome 12 in
p13 of that chromosome which leads to a rearrangement of the location of HMGA2
gene on the long arm of chromosome 12. Consequently this case was investigated
as a myoma with 12q14~15 rearrangements in long-term culture for 140 days until
the 22nd passage. The changes in chromosomes 2 and 12 stayed stable in all
passages. No more changes were observed in the later subcultures until the 11th
passage. In the last analyzed passage (P. 22), different clones of cells were
observed. First t(2;12) was seen in all clones of cells and also the only change in one
clone. Other clones including secondary changes had a ring chromosome 9, just one
cell showed a der(9) instead of r(9). Third clone of cells in addition to these two
changes revealed a karyotype with 45 chromosomes because of monosomy of
chromosome 6. A near-tetraploid karyotype with 92 chromosomes was observed in a
few cells starting from P.11. Changes of chromosome 9 started from P.12 by
existence of der(9), monosomy of chromosome 6 happened in P.18 and later, and
ring chromosome 9 was observed in P.22(Fig. 3.7).
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(a) (b)
(c) (d)
(e) (f)
Fig. 3.7: Karyograms of different passages (P) and the metaphase FISH figure of myoma 646 with
12q14~15 rearrangement in long-term culture.
(a): Primary material; 46,XX,t(2;12)(p21;p13)[11]; (b): P.12; 46,XX,t(2;12)(p21;p13),der(9); (c): P.11;
Tetraploidy; (d): P.18; 45,XX,t(2;12)(p21;p13),-6; (e): P.22; 46,XX,t(2;12)(p21;p13),-6,r(9);
12
der (12)
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(f): Primary material, metaphase dual-color FISH indicating a rearrangement of the HMGA2 locus. The
green fluorescent probe (RP11-269K4) located proximal (5‘) to HMGA2, the red fluorescent probes
(RP11-745O10 and RP11-293H23) located distal (3‘) to HMGA2, colocalized signals (green/red)
indicate a nonrearranged breakpoint region, whereas separated green and red signals indicate a
rearrangement of the chromosomal region 12q14~15 and HMGA2, respectively.
At the same time, the myoma 641.2 with an apparently normal karyotype and
HMGA2 expression in range of normal UL was cultured as the control for the
aberrant case. The cells were grown up to P.14 during 117 days. From the results?no
chromosomal changes were observed in the whole passages, just a few tetraploid
metaphases were revealed in the middle passages but not in the first and the last of
them. They were in a range of 2-4 metaphases in each objective slide.
Myoma 658.1 with karyotype formula: 46,XX,t(6;10)(p21;q22)[13]/46,XX,[8] and a
very high expression of HMGA1 was considered as a case with rearrangement of
6p21 and cultured for 147 days until 25th passage. This mosaic pattern was
observed only in the first passage followed by the growth of only normal clone of
cells. No other cytogenetic changes were observed in the long-term culture of these
cells with a high HMGA1 expression (Fig.3.8). Just tetraploid metaphases were
observed from P. 5 and in higher rate in P. 8. These cells showed a reduced rate in
last passages.
(a) (b)
Fig. 3.8: Karyograms of primary material and last passage (P) of myoma 658.1 with 6p21
rearrangements.
(a): Primary material; 46,XX,t(6;10)(p21;q22)[13]/46,XX[8]; (b): P.25; 46,XX
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As a control for myoma 658.1, the chromosome analysis of the normal case (myoma
659.2) in long-term culture was also carried out. The cells of this case were cultured
for 82 days and until 15th passage. The cultured cells of primary material of the
normal case showed a normal karyotype but with different single cell aberration
including translocation and ring chromosomes. All passages of this case showed a
normal karyotype (Fig.3.9). This normal UL did not reveal any tetraploid metaphase
either.
(a) (b)
(c) (d)
Fig. 3.9: Karyograms of myoma 659.2 with a normal karyotype and different single aberrations in the
primary culture.
(a): 46,XX,r(13),chrb(15)(q); (b): 46,XX,r(5); (c): 46,XX,t(1;1)(p36;q21); (d): 46,XX,?r(10)
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4. Discussion
UL are by far the most common gynecological tumors occurring in about 70-80% of
all women in their reproductive age (Cramer and Patel, 1990; Day Baird et al., 2003a;
Heinemann et al., 2003), and are accounted as the major reason for hysterectomy in
the United States, including approximately one-third of all hysterectomies (Wilcox et
al. 1994). Despite their high prevalence, concerning their rare malignant
transformation (<0.1% (Sandberg, 2005)), the etiology and pathogenesis of these
benign muscle tumors remain poorly understood.
The present study aimed at a better understanding of the biopathology of
leiomyomas, investigating a large series of UL in the cytogenetic and molecular
genetic analysis. This study tries to find the correlation between chromosomal
changes and gene expression of two involved genes in two major cytogenetic
subgroups of UL, those two genes which code the proteins of high mobility group AT-
hook proteins. This relation was analyzed to understand in more detail thes role of
HMGA proteins in the growth of mesenchymal benign tumors and their role in the
genome instability. Considering the abundant expression of these stem cell
chromatin associated proteins in embryo in the high proliferative stage with high
stability of genome, revelation of their function in the tumors could help us find more
about their biopathology and malignant transformation.
The available studies indicate that between 25-50% of diagnosed UL show
chromosomal aberrations (see for example; Sandberg, 2005; Gross et al., 2003;
Flake et al., 2003; Morton, 2000; Hennig, 1999). In this context only one study from
Japan stands alone (Kataokaa et al., 2003). The Japanese study based on the
analysis of a large series of myoma found abnormal karyotype only in 7% of UL (Tab.
4.1). The substantially different results of the Kataokaa et al., (2003) study and its
comparability to other studies may partially be explained by a biased selection of the
investigated tumors (e.g. a selection based on the size) and factors related to race.
To mitigate the selection bias and reduce the error, the present study is based on UL
samples obtained after hysterectomy or myomectomy and analysis of all detected
myomas (following a standard protocol). Our results of the cytogenetic analysis of
261 myomas indicate that 29.1% of myomas have an abnormal karyotype, which in
fact confirms the findings of the previous studies.
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Tab 4.1: Cytogenetic analysis of uterine leiomyomas in various studies.
Total
Samples
Normal
Karyotype
Aberrant
Karyotype
Region of study reference
261 185 (70.9%) 76 (29.1%) Germany Present study
166 145 (93%) 21 (7%) Japan Kataokaa et al., 2003
197 147 (75%) 50 (25%) Germany Hennig, 1999
182 129 (71%) 53 (29%) Belgium Brosens et al., 1998
114 73 (64%) 41 (36%) USA Rein et al., 1998
76 41 (54%) 35 (46%) Arizona Meloni et al., 1992
13 6 (46%) 7 (54%) Massachusetts Rein et al., 1991
63 39 (62%) 24 (38%) Sweden Pandis et al., 1991
90 59 (65.5%) 31 (34.5%) Sweden Pandis et al., 1991
35 21 (60%) 14 (40%)
Pennsylvania
(U.S)
Kiechle-Schwarz et al.,
1991
40 27 (67.5%) 13 (32.5%) Italy Vanni et al., 1991
189 145 (76.7%) 44 (23.3%) Swedwn Nilbert et al., 1990
9 5 (55.5%) 4 (44.5%) Arizona. Fan et al., 1990
Discussing the role of the cytogenetic abnormalities in the etiology of uterine fibroids
posed a question on whether these chromosomal changes are the first or second
event in the UL. Addressing this question, some studies do agree with the hypothesis
confirming the secondary nature.
The secondary nature of the chromosomal rearrangements is supported by the
findings of the studies suggesting that mosaic karyotype (normal/aberrant) myomas
are of the monoclonal origin (Mashal et al., 1994); and they are significantly smaller
in size than those solely composed of abnormal cells (Rein et al., 1998). Moreover, it
should be noted that at least half of UL have a normal karyotype.
It is proposed that UL mostly occur in the reproductive age (Kane, 2002). In this
study the age of patients ranged between 24-80 years old where age group between
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40 and 50 was the largest, with only few cases in patients under 30. The age
indicated above is the age of a patient at the time of operation, and not the incidence
of myoma or the age of their diagnosis. Sometimes, depending on the symptoms and
complications of tumor, the time period between incidence and diagnosis, as well as
diagnosis and treatment takes a very long time.
A regular size of 0.5 to 20 cm was commonly observed. The largest group in this
series of removed UL was 3-4 cm. It has been argued that the loss of genetic
material from chromosome 7 results in a less optimal growth in a myoma (Xing et al.,
1997). This finding was also supported by another study that found the deletion of 7
subgroup is involved in most of mosaic tumors while they are actually smaller in size
rather than chromosomally normal myomas (although the difference was not
statistically significant) (Morton, 1998). Rein et al. (1998) described that mosaic
karyotype myomas (normal/aberrant) are significantly smaller in size than those
solely composed of abnormal cells. Later, Hennig et al. (1999) showed that myomas
with 12q14~15 changes are significantly larger in size than myomas with a normal
karyotype and the tumors with deletion of chromosome 7 are significantly smaller in
size. Based on the results of the present study, mosaic UL had smaller size than
non-mosaic aberrant myomas but this difference was not significant (P=0.070).
Analysis of the tumor size in different cytogenetic subgroups revealed an agreement
with Hennig et al. (1999) (P=0.008). However there was no significant difference
(P=0.456) between normal myomas and UL with a deletion of 7q. Moreover no
significant difference (P=0.574) was noted between normal group and UL with 6p21
rearrangements.
Our analysis of multiple myomas indicates that even in a uterus with a multiple
myoma often just one nodule shows abnormal karyotype. The present finding was
also earlier confirmed in the studies by Pandis et al. (1994) and Kataokaa et al.
(2003).
4.1. Molecular cytogenetic analysis
Most available studies refer to t(12;14) or involvement of 12q14~15 region as most
prevalent subgroup in cytogenetically abnormal UL (for example Ligon and Morton,
2001; Gordon et al., 2003), with a frequency of about 20% of aberrant myomas
(Nilbert and Heim, 1990; Meloni et al., 1992; Gordon et al., 2003). Within this context
only one study from Germany showed a higher frequency (Hennig, 1999). This study,
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based on the analysis of a large series of myoma, found rearrangements of
12q14~15 in 46% of cytogenetic aberrant UL. However Sreekantaiah et al. (1994)
and Pandis et al. (1991) reported that a deletion of part of the long arm of
chromosome 7 was the most common aberration in UL. The present study also
confirmed that 12q14~15 rearrangements were most frequent aberration (27.6%)
followed by del(7q) (23.7%) in myoma.
This chromosomal abnormality of chromosome 12 is of particular interest because
the same region of 12q is also commonly rearranged in a variety of other
mesenchymal solid tumors e.g. lipomas, breast fibroadenomas, endometrial polyps,
pulmonary chondroid hamartomas (PCH), hemangiopericytomas, angiomyxomas
(Turc-Carel et al., 1986; Bullerdiek et al., 1997; Calabrese et al., 1991; Mandahl et
al., 1993; Vanni et al., 1993; Ozisik et al., 1994; Dal Cin et al., 1995; Fletcher et al.,
1995). As it is identified, the cytogenetic subtypes are correlated properly with a
different molecular pathogenesis of the disease. The critical gene located in the
chromosome 12q14~q15 region is HMGA2 (Ashar et al., 1995; Schoenmakers et al.,
1995). In normal cells, transcripts of the HMGA2 gene code primarily for the full-
length HMGA2 protein, a member of high mobility group protein AT-hook of which the
expression has been detected in UL with 12q14~15 rearrangements, but not in
matched normal myometrium (Gattas et al., 1999; Klemke et al., 2009). Quade et al.
(2003) mentioned that in the 12q15 rearrangements, mostly breakpoints are situated
5‘ and a few at the 3‘ location (usually found outside the HMGA2 coding region). It
was later supported by Klemke et al. (2009) that an extragenic breakpoint upstream
but in closer proximity of HMGA2 can be sufficient to trigger its overexpression.
Despite a wide distribution of breakpoints, intragenic as well as extragenic
(Kazmierczak et al., 1995; Hennig et al., 1996; Schoenmakers et al., 1999; Kurose et
al., 2000; Mine et al., 2001; Takahashi et al., 2001; Quade et al., 2003), the
molecular alterations resulting from the cytogenetic deviations generally seem to
include an upregulation of the gene (Tallini et al., 2000; Gross et al., 2003; Klemke et
al., 2009) and primarily affect the expression rather than the protein sequence
(Quade et al., 2003). Thus, overexpression of the full-length transcript or a truncated
or chimeric protein HMGA2 seems to be sufficient to trigger tumorigenesis (Klemke
et al., 2009). The term overexpression refers to an expression exceeding the
matching myometrium. It is found that high HMGA2 protein levels are a factor
correlated with a worse progression of malignant neoplasias, and HMGA2
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rearrangements can be frequently seen in benign tumors of mesenchymal origin
(Tallini and Dal Cin, 1999; Fedele et al., 2001). Moreover, it is observed that HMGA2
can act as a biomarker for some types of malignant tumors (Mahajan et al., 2010).
HMGA2 expression could be of prognostic significance in some cancers, e.g. non-
small cell lung cancer (Wu et al., 2008), metastatic breast cancer (Langelotz et al.,
2003), retinoblastoma (Mu et al., 2010), and cell carcinomas of the oral cavity
(Miyazawa et al., 2004). It can also serve as a valuable detector for distinguishing
malignant tumors from benign ones (Belge et al., 2008; Lappinga et al., 2010).
In description of the role of HMGA proteins in tumorigenesis, Bullerdiek (1997)
promoted the hypothesis that the overexpression of HMGA2 can induce an
embryonic chromatin configuration in cells and then empowers them with a stem-cell
like behavior. Further studies concerning the HMGA2 expression in embryonic stem
(ES) cells also supported this assumption (Li et al., 2006, 2007; Pfannkuche et al.,
2009). Li and colleagues (2006, 2007) confirmed that HMGA2 is consistently
associated with inter- and metaphase human ES cells chromatin and admited it as a
regulator of key developmental genes in these embryonic cells. Pfannkuche et
al.(2009) later came up with the idea that, by means of three independent DNA
binding domains, HMGA2 essentially promotes the plasticity of ES cell chromatin and
is associated with the maintenance of an undifferentiated cell state.
Although it was shown that UL with normal karyotypes can have cryptic inversions of
12q (Wanschura et al., 1997; Weremowicz and Morton, 1999), nevertheless, at least
50% of UL show a normal karyotype, meaning that no cytogenetically visible
chromosomal rearrangements can be seen and, moreover also by molecular
cytogenetic methods there is no evidence for the existence of submicroscopic
alterations of the HMGA2 locus in a considerable number of these cases
(Weremowicz and Morton, 1999). In addition, Klemke et al. (2009) indicated an
overexpression of HMGA2 mRNA also in karyotypically normal tumors. This study by
using quantitative RT-PCR in a large series of UL revealed a higher HMGA2
expression in cytogenetically normal karyotype fibroids in comparison to their
matched myometrium. This outcome suggests a more general role of HMGA2 and its
overexpression in the development of UL, and not only in the subgroup characterized
by 12q14~15 alterations.
The fact that the overexpression of HMGA2 is even present in the UL without
observed cytogenetically 12q14~15 rearrangements elevates the hypothesis that one
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of the main factors in the genesis of UL is a high level of a stem-cell chromatin
associated protein. For clarifying the HMGA2 overexpression despite a normal
karyotype detected by usual cytogenetic techniques; it could be said that, besides a
lack of cryptic HMGA2 rearrangement, distinguished by classical cytogenetics, a
selection of a group of cells without translocation during cell culture may admit the
apparent normality of karyotype.
The variability in the basic level of HMGA protein among the samples of the same
cytogenetic group of tumors might be explained by “mosaicism”. If this mutation was
an early or later event during tumor development, then the greater or lesser
proportion of cells would express the gene (Williams et al., 1997). Sometimes taking
a part of a big mosaic tumor could lead to a selecting of different clones of the same
tumor for different analysis. Another possibility can be the reflection of a specific type
of mutation that has occurred in each tumor (Williams et al., 1997), or reflecting
alterations during the menstrual cycle. These kind of alterations in the patterns of
gene expression have been investigated before, e.g., by Kayisli et al. (2007).
In spite of the monoclonal origin of UL (Townsend et al., 1970; Mashal et al., 1994;
Hashimoto et al., 1995; Zhang et al., 2006), the mutations of the gene are not
necessarily responsible for the overexpression of HMGA2. In several recent studies,
it is observed that microRNAs of the let-7 family regulate HMGA2 post-
transcriptionally (Lee and Dutta, 2007; Mayr et al., 2007; Park et al., 2007; Shell et
al., 2007; Kumar et al., 2008; Motoyama et al., 2008; Peng et al., 2008).
Nevertheless, the molecular mechanism which induce an overexpression, especially
where cytogenetically translocations are detectable with breakpoints in or close to the
chromosomal location domain of 12q14~15, are still to be studied and identified.
Likewise, there are also reports on the reduced expression of let-7 family members in
UL (Peng et al., 2008). Although the down-regulation of miRNAs decreases HMGA2
expression, other factors like loss of the let-7 complementary sites (LCS) in the 3’
UTR of HMGA2 can also be responsible for the deficiency in let-7- mediated
regulation (Mayr et al., 2007). The study by Klemke et al. 2010 shows that although
the loss of let-7 complementary sites is not associated with the HMGA2
overexpression in most UL, it seems to raise the effects of a HMGA2 transcriptional
deregulation in a small subset of UL (Klemke et al., 2010).
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The 14q23~q24 region, which is most often fused to 12q14~15, is also involved in
several mesenchymal benign tumors, including uterine leiomyomas, pulmonary
chondroid hamartomas, and endometrial polyps (Walter et al., 1989; Nilbert and
Heim, 1990; Rein et al., 1991; Dal Cin et al., 1993, 1995; Fletcher et al., 1995; Vanni
et al., 1995; Kazmierczak et al., 1995, 1996). Two candidate genes in this region of
chromosome 14 are ESR2 (Estrogen Receptor Beta Gene) (Pedeutour et al., 1998)
and RAD51L1 (a member of the RAD51 recombination repair gene family)
(Schoenmakers et al., 1999). The RAD51L1 gene is introduced as a translocation
partner for HMGA2 in leiomyoma (Schoenmakers et al, 1999; Ingraham et al., 1999).
This gene is involved actively in DNA repairs recombination, although such a
recombination is not detected to be catalyzed by the RAD51L1 protein (Takahashi et
al., 2001) and may be essential for cell proliferation (Shu et al., 1999).
Some other partner genes for HMGA2 have also been described, i.e., the COX6C
gene at 8q22~q23 (Kurose et al., 2000), the ALDH2 gene at 12q24.1 (Kazmierczak
et al., 1995), the enhancer of invasion (HEI10) gene at 14q11 (Mine et al., 2001).
Another cytogenetic subgroup is characterized by aberrations of 6p21, the location of
another member of HMGA family, HMGA1 (Friedmann et al., 1993). Rearrangements
of band 6p21 and overexpression of HMGA1 respectively have been observed
frequently in various mesenchymal tumors, including lipomas (Tallini et al., 1997),
pulmonary chondroid hamartomas (Xiao et al., 1997), breast hamartomas (Dal Cin et
al., 1997), and uterine leiomyomas (Sornberger et al., 1999; Tallini et al., 2000).
Moreover, results of the present study proved the higher expression of HMGA1 in the
6p21 group than that in the normal group (Hashemi Nezhad et al., 2010). Notably,
compared to fibroids with a normal karyotype, in these cases the upregulation of the
HMGA1 mRNA was much less stronger than that of HMGA2 mRNA in the case of
12q14~15 aberrations. As showed in different studies, HMGA1 plays a role in both
activation and suppression of the transcription of several genes, therefore, over
expression of HMGA1 in UL might facilitate activation or repression of a variety of
genes relevant to tumor growth and biology (Williams et al., 1997).
Furthermore, neoplastic transformation was associated with HMGA1 expression in
different human neoplasias such as prostatic cancers (Tamimi et al., 1993; 1996),
thyroid neoplasias (Chiappetta et al., 1995; 1998), pancreatic duct cell carcinomas
(Abe et al, 2000), breast carcinmas (Chiappetta et al., 2004), hepatocellular
47
carcinomas (Chang et al., 2005), lung cancers (Sarhadi et al., 2006), and
leukaemias.(Pierantoni et al., 2003). Furthermore, differential expression and
prognostic value of HMGA1 was shown in the subtypes of some tumors (van der Zee
et al., 2010).
Further studies have observed that the role of HMGA1a protein in both virus
integration and viral genome expression in host cells of immunodeficiency virus type
1 (HIV-1), human papilloma virus type 18 (HPV-18) (Hindmarsh et al., 1999; Farnet
and Bushman, 1997; Bouallaga et al., 2003; Henderson et al., 2004) and all of the
herpes simplex virus type 1 (HSV-1) (Matta and Panagiotidis, 2008).
In addition to the 6p21 group and normal cases, HMGA1 expression was analysed
also in two UL with 12q14~15 aberrations (myoma 151B and myoma 154).
Interestingly, the level of HMGA1 mRNA in these myomas (average=29.8) were also
higher than normal group (average=7.2), and much closer to the range of 6p21 group
(average=45) than that in normal UL (Fig. 3.6). As Williams et al. (1997) suggested?
these tumors may have acquired small mutations, undetectable by standard
cytogenetic techniques that lead to the ectopic expression of HMGA1 in the absence
of cytogenetic abnormalities. Aimed to reduce such missing, FISH analysis was
performed by using HMGA1 probes. From the results, no split was revealed for
HMGA1 gene in these two myomas. It is mentioned that, despite the apparent
differences in interacting partners of both genes (Arlotta et al., 1997), they have a
great extent of sequence and structural similarity (Tallini and Dal Cin, 1999) and a
high homology in their DNA-interacting domains. Therefore, it can be suposed that
HMGA1 and HMGA2 are able to replace each other functionally, at least in part.
Findings of this study do also agree with Williams et al. (1997) concerning the lack of
a significant correlation between HMGA1 levels and tumor size (Fig. 3.4A).
del(7)(q22), another non-random cytogenetic abnormality in UL is present in some
studies as most frequent abnormality in myomas (Nilbert and Heim, 1990; Pandis et
al., 1991; Meloni et al., 1992) and by the others as the second common
rearrangement in this tumor (Rein et al., 1991; Vanni et al., 1991; Ligon and Morton,
2000). del(7)(q22q32) is present in about 17-24% of karyotypically abnormal UL
(Nilbert and Heim, 1990; Hennig, 1999; Ligon and Morton, 2000). It is shown that
probably del(7) coexists with t(12;14) or t(1;6) (Nilbert et al., 1989). This idea
suggests that del(7q) is involved with the karyoypic evolution of leiomyoma, although
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the t(12;14) often occurs as the sole abnormality (Sait et al., 1989). Sargent et al.
(1994) found that these deletions and rearrangements of 7q22 region are more
consistent in UL than in any other tumors. It was shown that UL with chromosome 7
deletions or translocations are usually present in the mosaic form accompanied with
normal cells (Xing et al., 1997). From present results, in eight UL this anomaly was
present in a mosaic state accompanied with normal cells, however in three of them
other structural aberrations were observed with del(7). Although based on the finding
of this anomaly as the sole alteration in some UL, Ligon and Morton (2000),
proposed a possible role as an early genetic event for it in UL.
The observations of cell culture showed a slow proliferation pattern of myoma cells in
vitro in tumors with a deletion of chromosome 7, especially in the cases showing this
rearrangement as the sole change and subsequently a difficult chromosome analysis
with low number of reached metaphases. This suggests a possibility of the same
changes in the missed samples of chromosome analysis. This suggestion means a
higher frequency for this subgroup of aberrant UL. It was before stated that cells with
the del(7)(q22q32) are more likely to persist in cultures when the t(12;14) is also
present (Sandberg, 2005).
A large number of genes or growth factors, particularly those localized in the
commonly deleted area of 7q22 have been identified. A possible relationship
between insulin resistance genes and rearrangements at 7q21.3 has been postulated
(Sell et al., 1998). Existence of a novel tumor suppressor gene for uterine smooth
muscle tumors on the chromosome region 7q22 was suggested by the relatively high
frequency of loss of heterozygosity (LOH) in this region (van der Heijden et al.,
1998). It was indicated that approximately 30 genes have been mapped to the 7q22
region, from which the plausible candidate for smooth muscle tumor suppressors is
the COL1A2 gene, which encodes the a-2 chain of collagen type 1. Considering the
role of COL4A6 gene in the hereditary syndrome diffuse leiomyomatosis, COL1A2 is
an available candidate (Hudson et al. 1993). Nevertheless, COL1A2 seems to map
proximal to the upper boundary of the minimal deletion unit. Sandberg (2005)
believed that events at 7q may not be crucial to leiomyoma development. While it is
detected before that in the leiomyomas with del(7q) as the sole abnormality, HMGA2
expression was not found, its expression was confirmed in a tumor with
t(12;14)(q15;q24) and a del(7q) and another with a t(2;3;12)(q35;q21;q14) as the sole
change (Henning et al., 1997).
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Analysis of the expression of HMGA2 in the group of trisomy 12 as one type of non
random abnormality in UL showed no significant difference (P=0.268) between the
group of UL with trisomy 12 and normal group (Fig. 3.5). It could support the
hypothesis that rearrangements by intragenic as well as extragenic breakpoints of
HMGA2 gene can result in an overexpression (Quade et al., 2003; Klemke et al.,
2009).
Another often discussed anomaly in UL, monosomy of chromosome 22, was
observed in five cases. Loss of one chromosome 22 has been previously detected in
myomas (Gibas et al., 1988; Turc-Carl et al., 1988; Nilbert et al., 1989; Pandis et al.,
1990, 1991). Pandis et al. (1991) concluded that monosomy 22 is probably a non-
random secondary abnormality. The present finding is not contrary to this idea;
however one case showed monosomy 22 as the sole abnormality.
In the present study, 12 (15.8%) aberrant myomas showed a ring chromosome. Five
of them had a ring (1) of which four UL showed ring (1) with a t(12;14). Ring
formation and structural rearrangements of chromosome 1 as the secondary
changes in UL with t(12;14)(q14~15;q23~24) were discussed before by Nilbert et al.
(1988). It is likely that two mechanisms are involved in producing ring chromosomes.
The most common one is the breaking of both arms of the chromosome and loss of
distal segments. The loss of chromosomal material happens as the result of the
subsequent fusion of the ends. This classical pattern of ring chromosome formation
commonly induces multiple phenotypic effects (Gardner and Sutherland, 1989).
Another type of ring chromosome is created by telomere-to telomere fusion. In this
case little or no loss of chromatin may happen, and if the ring chromosome would be
lost, it might result in significant consequences, and then monosomy. It is assumed
that the instability of ring chromosome is produced by sister chromatid exchange
within the ring which may generate unstable variants (Therman, 1986).
Sawyer et al. (1992) illustrated that a primary cytogenetic event in solid tumors can
be the telomeric association which is a mechanism able to induce chromosome
instability through generating subclones with unstable chromosome intermediates,
and therefore ring chromosome formation and consequently monosomy.
In a recent review by Gebhart (2008) that listed cytogenetically analysed leiomyomas
with ring chromosomes, it is reported that in most of the cases the non-random
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involvement of chromosome 1 in the rings can be detected by cytogenetic and
molecular cytogenetic techniques. Polito et al. (1999) who applied FISH with PAC-
clones for HMGN2 (high-mobility group nucleosomal binding domain 2, located in
1p36.1), could not find any signal on the r(1): This can mean that HMG17 does not
have any mechanistic role in leiomyoma which is similar to what is seen in other
high-mobility proteins. In a few analyzed uterine leiomyomas, r(1) or r(1;?) were
found particularly as the sole karyotypic anomaly which is a part of a 2n=46
karyotype (Nilbert and Heim, 1990; Kiechle-Schwarz et al., 1991; Polito et al., 1999).
This is the same as Sandberg’s (2005) suggest, maintaining that, rings containing
chromosome 1 may be secondary changes in these tumors; while Pandis et al. in
1991 had suggested that r(1) formation is a preferred pathway in clonal evolution of
uterine leiomyomas.
Present findings showed r(1) as the secondary change after translocation or insertion
of chromosomes 12 and 14 in two tumors. Accompanied by this change in one
myoma, in other cases ring chromosomes were detected in mosaic karyotype with a
normal clone and/or with a clone of cells losing ring one.
4.2. Genome stability of UL
In order to investigate the role of HMGA proteins in genomic stability in a large series
of UL, different groups of cells showing different levels of HMGA2 expression were
considered and compared. Because of the low number of cases including 6p21
rearrangements and high expression of HMGA1, respectively, this analysis was
performed just for the UL with 12q14~15 rearrangements (Fig. 4.1). Unstable
condition for the cells was marked by metaphases including a structural single
aberration or a chromosome/chromatid break.
Normal cells with an undetectable or detectable HMGA2 expression at very low level
have a high genomic stability. As it is known malignant cells show various
chromosomal aberrations with a reduction of genomic stability. If it would be
accepted that HMGA2 impairs the integrity of genome and causes instability,
therefore this group of cells with high genomic instability should have a very high
expression of HMGA2, on the other hand, the stem cells with a high proliferation rate
and extra expression of HMGA2 will be expected to reveal relatively high instability in
their genome. Furthermore, it is known for the benign cells including 12q14~15
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rearrangements to have a high level of HMGA2 protein; therefore, this group of cells
should also have a behavior like stem cells.
Normal cells
Stem cells and cells
with 12q14~15
rearrangements
Malignant cells
Malignant cells
Stem cells and cells
with 12q14~15
rearrangements
Genome instability
HMGA2
expression
Fig. 4.1: Real and expected correlation of HMGA2 expression and genomic instability. Red boxes:
expected place for each group; green boxes: real place for each group of cells.
To support the stated assumption some studies have linked HMGA proteins with an
increased genomic instability due to a reduced capacity to repair DNA damage, for
example inhibition of nucleotide excision repair by HMGA1 (Adair et al., 2005),
repression of ERCC1 gene by HMGA2 (Borrmann et al., 2003), and suppression of
nonhomologous end joining (NHEJ) repair by overexpression of HMGA2 (Li et al.,
2009). In a different cell type HMGA2 has been shown to bind directly to, and
negatively regulate, the promoter of an important gene involved in the regulation of
nucleotide excision repair (ERCC1) (Borrmann et al., 2003). Using the fibroblasts
transfected by a construct encoding HMGA2 as a hallmark of deficient NHEJ, Li et
al., (2009) argued that HMGA2 protein acts as an inhibitor of NHEJ. Through a
reduction of DNA stability it facilitates the accumulation of chromosomal aberrations
which is a central feature of tumorigenesis.
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But the present results of the analysis of HMGA2 expression using real time RT-PCR
and cytogenetic investigation in these groups do not agree with this assumption.
Investigations of three groups of myomas (UL showing rearrangements of 12q14~15
region without single aberration or chromosome/chromatid break (N=16), myomas
with an apparently normal karyotype without single aberration or
chromosome/chromatid break (N=151) , and all UL affected with single aberrations or
chromosome/chromatid breaks (N=46)), revealed that there is no difference between
the percentage of cells including a single structural aberration or
chromosome/chromatid break between all UL with 12q14~15 rearrangements and all
normal myomas. Considering the gene expression, there was no significant
difference between affected group with a single structural aberration or
chromosome/chromatid break and the UL without such changes, moreover there was
no difference between the expression of HMGA2 in affected UL with just one event
and myomas including more than one chromosome/chromatid break or single
aberration. In addition, it is proved the malignant cells with relatively higher levels of
HMGA2 and known high genome instability; express HMGA2 in a lower level than
benign tumors including 12q14~15 rearrangements (Markowski et al., 2010b). It is
true in stem cells also that this group of cells has a high expression of HMGA2
despite their good genome stability.
In summary, stem cells and benign cells with involvement of 12q14~15, despite an
overexpression of HMGA2, protect the stability of the genome well. In contrast,
malignant cells with high genomic instability express HMGA2 in a lower level than
benign and stem cells (Fig. 4.1). Bullerdiek and Rommel (2010) proposed that in this
context a plausible assumption is that the cytogenetically unstable cells displaying
sporadic translocations or dicentrics are those with strong overexpression of the
recombinant HMGA2 in a range usually not found during embryonic development.
At the same time, it should not be forgotten that HMGA2 is a protein abundantly
expressed during embryonic and fetal life (Rogalla et al., 1996; Li et al., 2007) and it
is difficult to believe that this protein per se destabilizes the genome. On the other
hand the benign behavior with rare malignant transformation in UL (Sandberg, 2005;
Morton, 1998) and other benign tumors proves the high genomic stability in these
cells.
For an explanation, it seems plausible to assume that the cells having 12q14~15
abnormalities protect the genome despite their high HMGA2. It might be the
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existence of other factors accompanying high HMGA2 or its other role, which
counterbalances its effect in the induction of genome instability.
Narita and colleagues introduced a novel role for HMGA proteins; these proteins also
act in tumor suppressor networks by having a role in cellular senescence and
heterochromatin formation (Narita et al., 2006). They showed that HMGA protein as a
promoter of tumorigenesis joins p16Ink4a tumor suppressor in inducing proliferative
arrest and senescence through their assistance in repressing proliferation-associated
genes. Although in somatic stem cells, there is a link between HMGA2 and the
CDKN2A locus (encoding p16INK4a and p19Arf) observed, the expression of this
locus is related directly with cellular senescence control in most of the cell types and
can be repressed by HMGA2 ( Nishino et al., 2008). A recent investigation on the
role of HMGA2 also supports the mentioned protection assumption, when another
pathway correlated with HMGA2 in the growth and genome stability of UL was
exhibited (Markowski et al., 2010a). This study revealed a high expression of
senescence-associated p19Arf in the presence of overexpression of HMGA2 in UL
with 12q14~15 rearrangements. The results identify the p19Arf-TP53-CDKN1A
pathway as a balancer in the growth and genomic stability of UL in presence of a
high level of HMGA2. The S phase of cell cycle is engaged in supporting the integrity
of the genome and inhibiting genetic instability (Myung et al., 2001).
Therefore, the role of the known guardian of the genome, tumor suppressor protein
p53 should be attended. p53, a transcription factor, encoded by the TP53 gene,
located on the short arm of chromosome 17 (17p13.1)( Matlashewski et al, 1984;
McBride et al, 1986; Isobe et al., 1986; Kern et al., 1991), plays a role in apoptosis,
senescence (an irreversible growth arrest), genetic stability, and inhibition of
angiogenesis. The data by Izadpanah et al. (2008) presented that there is a
coincidence between the arrest in the S phase of the cell cycle, detected in the long-
term in vitro culture of human mesenchymal stem cells (MSCs) and the considerably
suppressed expression of p53. Formerly, Bartek and Lukas (2001; 2003) admitted
that S phase checkpoint mechanisms arrest the cell cycle in a p53-independent
fashion.
Responding to DNA damage, p53 is able to inhibit the progression through the G1-S
checkpoint in the cell cycle. In the case of prevalent DNA damage, it will activate the
DNA repair proteins, and if the damage is not being repaired, p53 starts apoptosis.
Therefore, the mutated cells are removed from the cell cycle by apoptosis, the
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programmed cell death, and afterward, cell division will continue with health cells and
the stability of genome will be protected well. Therefore, considering the stability of
genome in the benign tumors with high expression of HMGA2, an intact p53 pathway
is necessary.
4.3. Long-term expansion of myoma cells
For further investigations on myoma growth and HMGA proteins in the present study,
a long-term in vitro expansion was performed on four UL with different HMGA levels:
one with 12q14~15 rearrangement and very high level of HMGA2 (myoma 646),
another one including 6p21 aberration and high HMGA1 expression (myoma 658.1),
and in the same time for each case, one normal myoma as control (no. 641.2 and
659.2). All four cases, especially myoma 646 had in the beginning a fast proliferation
pattern.
The cell cycle is a notably organized process which is result in for the loyal
duplication and transmission of genetic information through the cell generations
(Israels and Israels, 2001). In vitro, the primary mammalian cells are able to replicate
to approximately 50 cumulative population doublings, after which the division of cells
stops (Hayflick and Morrhead, 1961). This phenomenon is called Hayflick limit, and is
widely distinguished as the replicative senescence. A basic step of quick proliferation
can be seen in the proliferative lifespan of fibroblast cultures, which is succeeded by
a phase of declining replicating frequency. The next stage is that of replicative
senescence in which the cultures are not able to proliferate more (Vande Berg and
Robson, 2003). The studies by Campisi et al. (1996); Faragher and Kipling (1998)
came up with the assumption that the replicative senescence resulted from the
limited lifespan of diploid cells is a key mechanism behind human aging in vivo. A
proposed mechanism in regualting replicative senescence is the gradual erosion of
chromosomal telomeres (telomere-dependent senescence) (Harley et al., 1990). The
factor which can probably be of help in identifying the number of earlier cell divisions
and thus, the replicative age of a considered cell, is the telomere erosion degree and
the telomere length estimation (Harley et al., 1990); and additionally, as Baird et al.,
(2003b) confirms in his results, they can even help us find the potentiality of that cell
to replicate further. Telomere shortening happens as the result of different processes,
from which the end-replication case of DNA synthesis can be mentioned. This event
can impress all cells lacking active telomerase (Enoch et al., 2009). Notable is to say
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that; the somatic cells such as fibroblasts are not yet seen to express telomerase
(Klapper et al., 2001), but tumor cells (Newbold, 2002) and stem cells (Wai, 2004)
do, therefore it is probable that they do not encounter telomerase shortening which is
by itself an introduction for indefinite replication.
A marked decrease in telomerase activity in progressively increasing passages of
MSCs derived from the bone marrow and adipose tissue has previously been
reported (Izadpanah et al., 2006). Loss of telomeres is discussed as one possible
mechanism of chromosome instability (Blackburn, 2001).
It is mentioned that the cells of benign tumors undergo only a few divisions before
senescence of the culture, but unbalanced chromosomal abnormalities cause an
increased in vitro lifetime (Stern et al., 1990). The cells of UL show a limited and slow
growth potential in vitro despite their high growth potential in vivo (Stern et al., 1991;
Sandberg et al., 2005).
From considered samples, the normal UL grew until 14-15th P and then underwent
replicative senescence. Both did not reveal any chromosomal aberration, just a few
tetraploid metaphases (in a range of 2-4 metaphases in each objective slide) in the
middle passages, but not in the first and the last of them in myoma 641.2.
Interestingly, myoma 659.2, a normal case with different single cell aberration in the
primary culture, did not show any aberration even tetraploidy either (Fig. 3.9).
Retaining the normal diploid karyotype in human mesenchymal stem cells in an
extended culture was reported before (Izadpanah et al, 2008). According to their
findings, a significant percentage of cycling human MSCs was arrested in S phase of
the cell cycle at P20 and higher.
Tetraploidy, the result of abnormal mitotic division (Izadpanah et al., 2008), is not
rare in fibroblast cultures (Bullerdiek und Rommel, 2010). It was also reported in the
study by Izadpanah et al. (2008), in an expanded MSCs cultures. During further cell
divisions, the cells lose their ability to maintain chromosome stability. Long-term
cultures can lead to changes in cell cycle kinetics and produce a tetraploidy
(Izadpanah et al., 2008). It has suggested that tetraploidy may result from
endoreduplication, which has been associated with p53 inactivation (Vogel et al.,
2004). This hypothesis was supported by introducing a p53-dependent pathway as
an intrinsic capacity to eliminate tetraploid cells (Fujiwara et al., 2005; Shi and King,
2005).
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Myoma 658.1 with karyotype formula: 46,XX,t(6;10)(p21;q22)[13]/46,XX,[8] and a
very high expression of HMGA1 grew up to P.25. This mosaic pattern was followed
by the growth of only normal clone of cells after first passage. Any chromosomal
alterations were observed in the long-term culture (Fig. 3.8) except teteraploid
metaphases starting from P.5. The repression of aberrant cells by normal cells has
been previously described (Stern et al., 1990).
Long-term culture of myoma 646 with 12q14~15 rearrangement and high HMGA2
expression exhibited a near-tetraploid karyotype with 92 chromosomes in a few cells
that started from P.11, changes of chromosome 9 started from P.12 by existence of
der(9), monosomy of chromosome 6 in P.18 and later, and ring chromosome 9 in
P.22 (Fig. 3.7). Derivative chromosome 9 and a monosomy of chromosome 6 in long-
term culture of pleomorphic salivary gland adenomas were also observed by Stern et
al. (1990). Ring chromosome 9 with appearance from P. 22 might be a
transformation of the derivative chromosome 9 into a ring.
Presumably the new aberrations are caused by gradual adaptation of the cells to
their culture conditions. Different factors were counted to contribute in these
changes, such as: technique of chromosome preparation, incubation time of cells in
cell culture until chromosome analysis, number and quality of the analysed
metaphases (Stern, 1992), and culture medium, some extensive studies showed that
the Chang-medium increases the chromosomal instability and various chromosome
aberrations (Bui et al., 1984; Krawczun et al., 1989; Bartnitzke et al., 1992).
After a long-term in vitro culture, the spontaneous conversion of cells may affect the
chromosomal stability of cells (Rubio et al., 2005; Miura et al., 2006). For the cells of
myoma 646, it could be suggested that long life in vitro accompanied with other
factors such as the existing 12q14~15 aberrations and high level of HMGA2 with an
enormous mitotic division and telomere shortening has strongly promoted the
chromosomal instability and further aberrations.
The behavior of the fibroids in vitro by a limited growth potential and lack of
spontaneous immortalization was characterized (Stern et al., 1991; Carney et al.,
2002). Further cultures of rapid proliferative myoma 646 proved this matter again.
The cells underwent senescence in P. 26. Histopathology survey also demonstrated
a typical leiomyoma pattern for this case. Another analysis on a series of UL
including case no. 646, by Markowski et al. (2010b), explained the high proliferative
rate of this sample despite its benign identity. This recent study has compared the
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expression of HMGA2 and senescence-associated p19Arf in the tissue and matching
cell culture cells of UL. Results revealed a marked decrease of the HMGA2 mRNA in
culture in most cases with overexpression of HMGA2, and a clearly increased
expression of p19Arf associated with the decrease of HMGA2 in normal and 12q14~15
aberrant UL. This increased level of p19Arf can be a good reason for fast senescence
in both normal and aberrant myoma cells. In an exceptional condition, myoma 646
revealed a lower p19Arf RQ value in culture rather than in tissue. This low level of
senescence-associated protein can explain the rapid mitotic division in these cells.
Of note, recently recurrent mutations of MED12 have been identified in UL (Mäkinen
et al., 2011) that seem to occur independent of 12q14~15 translocations (Markowski
et al., 2012). Interestingly, these mutations have also been found in rare cases of
leiomyosarcomas (Pérot et al., 2012; Markowski et al., 2013).
In conclusion, the acquired knowledge from this study could help to a better
understanding of the biopathology, development and progression of fibroids. They
are also a confirmation of the findings of the previous studies, while offering
promoted knowledge concerning the pathogenesis of UL. Moreover, considering the
widespread presence of HMGA proteins in various benign and malignant tumors, the
present findings in addition to future investigations, can provide new approaches in
the development of diagnosis and therapies of the tumors. The goal is to put fewer
burden on patients and reduce the health system financial costs.
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Overexpression of HMGA2 in Uterine Leiomyomas
Points to its General Role for the Pathogenesis
of the Disease
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Christiane Frantzen,2 Ernst Heinrich Schmidt,3 Gazanfer Belge,1 and Jo¨rn Bullerdiek1,4*
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An overexpression of HMGA2 is supposed to be a key event in the genesis of leiomyoma with chromosomal rearrange-
ments affecting the region 12q14-15 targeting the HMGA2 gene, but gene expression data regarding differences between
uterine leiomyomas with and those without 12q14-15 aberrations are insufﬁcient. To address the question whether
HMGA2 is only upregulated in the 12q14-15 subgroup, the expression of HMGA2 was analyzed in a comprehensive set of
leiomyomas (n ¼ 180) including tumors with 12q14-15 chromosomal aberrations (n ¼ 13) and matching myometrial tis-
sues (n ¼ 51) by quantitative RT-PCR. The highest expression levels for HMGA2 were observed in tumors with rearrange-
ments affecting the region 12q14-15, but although HMGA2 is expressed at lower levels in leiomyomas without such
aberrations, the comparison between the expression in myomas and matching myometrial tissues indicates a general upre-
gulation of HMGA2 regardless of the presence or absence of such chromosomal abnormalities. The signiﬁcant (P < 0.05)
overexpression of HMGA2 also in the group of ﬁbroids without chromosomal aberrations of the 12q14-15 region suggests
a general role of HMGA2 in the development of the disease. VC 2008 Wiley-Liss, Inc.
INTRODUCTION
Uterine leiomyomas (UL, ﬁbroids) are the
most frequent gynecological tumors and, despite
being benign, constitute an enormous public
health burden. Among the symptoms caused by
uterine leiomyomas are menorrhagia, abdominal
pain, and infertility (Stewart, 2001). Their actual
prevalence is still a matter of debate and seems
to vary among populations, but at least one third
of women aged 30 years or older have one or
more UL (Cramer and Patel, 1990; Baird et al.,
2003; Heinemann et al., 2003). Their incidence
seems to be higher in African American than in
European American or European women (Mar-
shall et al., 1998).
Currently, mutations of the two human genes
encoding high mobility group proteins of the
HMGA type, i.e., HMGA1 and HMGA2 have
been assumed to be causally linked with the de-
velopment of subsets of uterine leiomyomas.
Both genes encode members of the so-called
high mobility group proteins. HMGA proteins are
capable of binding to the minor groove of AT-
rich DNA with three DNA-binding domains (so-
called AT-hooks), thus inducing conformational
changes in chromatin structure and enabling the
regulation of the expression of various target
genes. In addition, they can interact with other
proteins by means of their acidic domain (Fusco
and Fedele, 2007). HMGA1 and HMGA2 map to
chromosomal bands that are targeted by nonran-
dom structural chromosomal abnormalities found
in uterine leiomyomas, i.e., 6p21 for HMGA1
(Kazmierczak et al., 1996) and 12q14-15 for
HMGA2 (Ashar et al., 1995; Schoenmakers et al.,
1995). Usually, these regions are affected by chro-
mosomal translocations but inversions can occur
as well with structural chromosomal aberrations
affecting 12q14-15 being much more frequent
than those affecting 6p21 (Nilbert and Heim,
1990). The molecular alterations resulting from
the cytogenetic deviations generally seem to
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include an upregulation of the genes (Tallini
et al., 2000; Gross et al., 2003). With regard to
HMGA2, a considerable fraction of the chromo-
somal breakpoints has been assigned to regions
outside the open reading frame of the gene, thus
primarily affecting its expression rather than its
protein sequence (Quade et al., 2003). Thus,
overexpression of HMGA2 seems to be sufﬁcient
to trigger tumorigenesis. It is obvious that an
enhanced level of HMGA2 is pathogenetically rel-
evant in a subset of some 10–20% of uterine leio-
myomas (Hennig et al., 1999), but it remains an
open question whether or not an increased level
of HMGA2, compared to normal myometrium,
may characterize also leiomyomas that do not
have HMGA2 rearrangements. A recent study by
Peng et al., (2008) suggests that upregulation of
HMGA2 may be a more general phenomenon in
UL but the analyzed tumors were not genetically
classiﬁed and no matched samples were analyzed
individually by quantitative RT-PCR. Herein, we
have quantitated the level of HMGA2 mRNA in a
large series of uterine leiomyomas.
MATERIALS AND METHODS
Tissue Samples
Samples of uterine leiomyomas and myome-
trium were snap frozen in liquid nitrogen imme-
diately after surgery and stored at 80C. In case
of UL another part of the tumor was used for cell
culturing and karyotyping. Informed consent was
obtained from all patients.
For ﬂuorescence in situ hybridization (FISH)
analyses HOPE (HEPES-glutamic acid buffer
mediated organic solvent protection effect)-ﬁxed,
parafﬁn-embedded tissue sections were used.
The tissues were cut into 5 lm sections which
were subsequently used for FISH analyses.
RNA Isolation, Reverse Transcription, and
Quantitative RT-PCR
RNA was isolated from fresh-frozen tissue sam-
ples with the RNeasy Mini Kit (Qiagen, Hilden,
Germany) including DNase treatment according
to the manufacturer’s instructions and quantitated
by spectrophotometry. After reverse transcription
of 250 ng of total RNA using M-MLV RT (Invi-
trogen, Karlsruhe, Germany) and random hexam-
ers, the HMGA2 mRNA levels were determined
by relative quantiﬁcation referring to the expres-
sion of 18S rRNA. Real-time PCR was performed
on a 7300 Real-Time PCR System with Assay
No. Hs00171569_m1 (Applied Biosystems, Darm-
stadt, Germany) for the detection of HMGA2 and
primers and probe for 18S rRNA as described
previously (Belge et al., 2008).
Analysis of Gene Expression
The relative expression was calculated by the
DCt method, using 18S rRNA as endogenous con-
trol and by choosing the HMGA2 expression of a
myometrial sample as calibrator. The signiﬁcance
of differential HMGA2 expression between the
different groups (myometrium, myoma with and
without 12q14-15 aberrations) was determined by
Student’s t-test.
Cell Culture
After surgery, samples of primary tumors were
stored in Hank’s solution with antibiotics (200
IU/ml penicillin, 200 lg/ml streptomycin). For
cell culture the tumor samples were minced and
treated with 0.26% (200U/ml) collagenase (Serva,
Heidelberg, Germany) for 5–8 hr. After centrifu-
gation, the pellet was resuspended in culture me-
dium (TC 199 with Earle’s salts supplemented
with 20% fetal bovine serum, 200 IU/ml penicil-
lin, 200 lg/ml streptomycin) and incubated at
37C and 5% CO2.
Chromosome Analyses
For chromosome analyses exponentially grow-
ing cultures of leiomyoma cells were used. Meta-
phase chromosome spreads were prepared by
using colcemid (0.06 lg/ml for 1 hr) to arrest cul-
tured cells during mitosis. A hypotonic solution
(culture medium and aqua bidest in a 1:6 ratio)
and the ﬁxative (methanol and acetic acid in a
3:1 ratio) were then applied sequentially. Finally,
the chromosome suspension was dropped onto
glass slides. The chromosomes were GTG-
banded according to routine techniques. Karyo-
type description followed ISCN (2005).
HMGA2-Speciﬁc Break-Apart Probes and FISH
For FISH three BAC clones were used as
break-apart probes. RP11-745O10 (AC078927)
and RP11-293H23 (AC012264) are located distal
(30) to HMGA2. RP11-269K4 (AQ478964 and
AZ516203) is located proximal (50) to HMGA2.
Labeling was performed by nick translation
(Roche Diagnostics, Mannheim, Germany) either
with digoxigenin (RP-269K4) or biotin (RP11-
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745O10 and RP11-293H23). For each FISH
experiment 2 ng/ll of the distally located probes
(RP11-745O10 and RP11-293H23) and 3 ng/ll of
RP11-296K4 were used in 15 ll hybridization
solution containing 50% formamide, 2SSC, 10%
dextrane sulfate and 105 ng/ll COT human
DNA.
FISH analysis on metaphase preparations was
performed after GTG banding of the metaphase
spreads. Treatment of metaphases and subse-
quent FISH experiments were performed as
described previously (Kievits et al., 1990) with a
few modiﬁcations. For one slide 25 ll of hybrid-
ization mixture were used. Codenaturation was
performed on a Mastercycler gradient (Eppen-
dorf, Hamburg, Germany) for 3 min at 80C fol-
lowed by O/N hybridization in a humidiﬁed
chamber at 37C. Posthybridization was per-
formed at 61C for 5 min in 0.1SSC. Subse-
quent treatment of slides was performed as
described previously (Kievits et al., 1990). For
detection of the hybridized probes antidigoxige-
nin ﬂuorescein fab fragments (Roche Diagnostics)
and Cy3-conjugated streptavidin (Dianova,
Hamburg, Germany) were used. Slides were
counterstained with DAPI (0.75 lg/ml) (Vector
Laboratories, Burlingame, CA).
For FISH, formalin-ﬁxed, parafﬁn-embedded
(FFPE) tissue sections were deparafﬁnized with
diethylether. Protease digestion was done with a
pepsin ready-to-use solution (DCS, Hamburg,
Germany) for 12–17 min. After dehydration in a
70%, 80%, and 95% ethanol series the sections
were postﬁxed with 1% formaldehyde in 1PBS
for 15 min. Prior to codenaturation the sections
were dehydrated again. Codenaturation was per-
formed on a Mastercycler gradient (Eppendorf)
for 5 min at 85C followed by O/N hybridization
in a humidiﬁed chamber at 37C. Posthybridiza-
tion was performed at 42C or 61C for 2 min in
0.4SSC/0.3%NP-40. Subsequent treatment of
slides and detection of hybridized probes were
performed as described for FISH on metaphase
preparations.
Slides were examined in an Axioskop 2 plus
ﬂuorescence microscope (Zeiss, Go¨ttingen, Ger-
many). Images were captured with an AxioCam
MRm digital camera and were edited with Axio-
Vision (Zeiss). For metaphase preparations, 10
metaphases were examined. For analysis of
FFPE tissue sections at least 100 nonoverlapping
nuclei from different (at least three) areas of the
tumors were scored. Nuclei with two colocalized
red/green signals (RG) were scored as normal.
Nuclei with one colocalized red/green signal, one
single red, and one single green signal
(1RG1R1G) were scored as positive for HMGA2
rearrangement.
RESULTS
For this study 180 uterine leiomyomas from
100 patients have been investigated by qRT-
PCR for the expression level of HMGA2. A total
of 57 myometrium samples from uteri removed
because of the occurrence of UL were investi-
gated as well. For 51 of these samples, matching
tissue from one or more leiomyomas was avail-
able. All UL have been karyotyped successfully
based on at least 10 G-banded metaphases show-
ing a resolution of 400 bands per haploid set or
higher.
Based on cytogenetics the group of UL was
further subdivided into those showing aberrations
of chromosomal region 12q14-15 (n ¼ 13; Table 1)
and those with an apparently normal karyotype or
other clonal aberrations (n ¼ 167), respectively.
As to these three groups, i.e., myometrium, UL
with 12q14-15 changes, and other UL HMGA2
expression was determined by qRT-PCR using
fresh-frozen samples. The average relative
HMGA2 mRNA expression was 1.99 for the myo-
metria and 261.41 for all UL. When distinguish-
ing between both subgroups of UL outlined
above average expression levels were 3213.78 for
UL with aberrations in the chromosomal region
12q14-15 and 31.59 for those without changes in
this region, respectively.
Thus, even within the group of UL without
cytogenetically detectable rearrangements of the
HMGA2 locus at 12q14-15 HMGA2 mRNA was
expressed at a higher level than in myometrium
(Fig. 1). Differences between all leiomyomas and
myometrium as well as between leiomyomas
without 12q14-15 aberrations and myometrium
were statistically signiﬁcant (P < 0.005 and P <
0.05, respectively). Furthermore, an individual
analysis of the matched samples (51 myometrial
tissues and 107 corresponding UL) was per-
formed. The mean HMGA2 expression was 11.37
in karyotypically normal UL (n ¼ 101) and 1.77
in the corresponding myometrial tissues (n ¼ 51).
The results clearly show that in nearly all cases
within each of the paired samples the leiomyo-
mas showed higher HMGA2 expression than the
corresponding myometrium (Fig. 2).
One case with a normal karyotype and an
unexpectedly high HMGA2 expression as well as
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a second myoma with a cytogenetically visible
t(12;14) and a rather low HMGA2 expression were
checked by interphase FISH. In the cytogeneti-
cally normal myoma, FISH showed HMGA2 dis-
ruption in 23% of the cells (Fig. 3, Table 1). The
tumor with visible t(12;14) but low expression of
HMGA2 showed two colocalized signals in 98% of
the nuclei, indicating an intact HMGA2 locus.
Metaphase FISH was also done on one case
with a t(12;14)(q15;q24) (Fig. 4). Interestingly,
the probe located proximal to HMGA2 (RP11-
269K4) showed three signals: on the normal chro-
mosome 12, the derivative chromosome 12, and
the derivative chromosome 14 (Fig. 4C), indicat-
ing a breakpoint located 50 of HMGA2. The
approximately 16kb distance between the probe
RP11-269K4 and the 50 end of HMGA2 suggests
that the breakpoint was located approximately
20kb upstream of HMGA2.
DISCUSSION
Despite their high prevalence the etiology and
pathogenesis of UL remain poorly understood.
Mutations of the gene encoding the high mobility
group protein HMGA2 have been suggested to
cause a subset of uterine leiomyomas (Schoen-
makers et al., 1995; Hennig et al., 1999). As a
Figure 1. Relative quantiﬁcation of the HMGA2 expression in uterine leiomyomas and myometrial
tissues. Green bars: Myometrium; yellow bars: UL without cytogenetically detectable aberrations of
chromosomal region 12q14-15; red bars: UL with 12q14-15 aberrations.
TABLE 1. Karyotypes of the 13 Leiomyomas with Chromosome 12 Aberrations and Results of Interphase FISH with HMGA2
Speciﬁc Break-Apart Probes
Karyotype
Relative HMGA2
expression
FISH results
(2RG/1RG1R1G)a
46,XX,inv(5)(q15q31 33),t(12;14)(q15;q24)[13] 8.6 98/1
46,XX,t(12;15;14)(q15;q26;q24)[20]/46,XX[1] 302.3 –
46,XX[36] 894.5 72/23
– 993.3 41/51
46,XX,der(1)r(1;2),t(12;14)(q15;q24)[4]/46,XX,t(12;14)(q15;q24)[13] 1047.8 m
46,XX,t(12;14)(q15;q24)[9]/46,XX[3] 1327.3 –
46,XX,r(1),t(1;12;14)(p36.3;q14;q24)[19] 1722.5 –
46,XX,t(2;12)(q33;q13)[17] 2381.6 –
46,XX,der(12),der(14)?ins(14;12)[8]/46,idem,r(1)[4] 3444.3 –
46,XX,t(3;5;12)(q23 25;p13 15;q13 15)[11]/45,XX,idem,-22 [10] 4450.7 –
46,XX,t(12;14)(q15;q24)[5]/46,XX[9] 5906.1 –
45,XX,t(12;14)(q15;q24),der(14)t(12;14)(q15;q24),-22[15] 7760.3 –
45,XX,t(12;14)(q15;q24),der(14)t(12;14)(q15;q24),-22[15] 11539.7 –
aPercentage of nuclei either with two colocalized signals (2RG) or with one colocalized, one single red and one single green signal (1RG1R1G) indi-
cating a HMGA2 rearrangement.
m, FISH was performed on metaphase preparations (Fig. 4). All 10 metaphases showed a breakpoint upstream of HMGA2.
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rule, this subset is characterized by cytogeneti-
cally visible structural chromosome alterations
affecting chromosomal region 12q14-15. HMGA2
has been identiﬁed as the target of these altera-
tions (Schoenmakers et al., 1995) and despite a
wide distribution of breakpoints, intragenic as
well as extragenic (Kazmierczak et al., 1995;
Hennig et al., 1996; Schoenmakers et al., 1999;
Kurose et al., 2000; Mine et al., 2001; Takahashi
et al., 2001; Quade et al., 2003), the key mecha-
nism by which the chromosomal alterations
contribute to tumorigenesis seems to be an upre-
gulation of the HMGA2 gene leading to overex-
pression of the full-length transcript or a
truncated or chimeric protein. Nevertheless, the
majority of UL lack cytogenetically visible
chromosome alterations and also by molecular-
cytogenetic methods there is no evidence that
submicroscopic alterations of the HMGA2 locus
occur in a considerable number of these cases
(Weremowicz and Morton, 1999). On the other
hand, HMGA2 overexpression could play a more
general role in the development of UL, and not
only in the subgroup characterized by 12q14-15
alterations. Roughly 10 years ago the hypothesis
was advanced that HMGA2 overexpression induces
an embryonic chromatin conﬁguration in cells, thus
re-endowing them with a stem-cell like behavior
(Bullerdiek, 1997). This assumption was further
supported by recent studies on the HMGA2 expres-
sion in embryonic stem cells (Li et al., 2006, 2007).
Here, we have shown that also UL without
cytogenetically detectable 12q14-15 rearrange-
ments overexpress HMGA2. This supports the
assumption that an elevated level of a stem-cell
chromatin associated protein is one of the key
events in the genesis of UL. Of particular note,
the expression of HMGA2 in myomas almost
always exceeded that of the corresponding myo-
metrium (Fig. 2). Apparently, the basic level of
HMGA2 varies among the samples. Possibly, this
could reﬂect changes throughout the menstrual
Figure 3. Dual-color FISH performed on interphase nuclei of a
leiomyoma with cytogenetically normal karyotype. One nucleus show-
ing two colocalized red/green signals (2RG, left) and a second nucleus
with one colocalized red/green and one single red and green signal
(1RG1R1G, right), respectively, indicating a rearrangement of
HMGA2.
Figure 2. HMGA2 expression in UL (crosses) and matching myometrial tissues (open circles) in
increasing order of expression in myometrial tissues. Triangles indicate UL with 12q14-15 aberrations.
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cycle. Such alterations in gene expression pat-
terns have been described, e.g., by Kayisli et al.
(2007). Herein, the term overexpression refers to
an expression exceeding that of the matching
myometrium. Despite the monoclonal origin of
UL (Townsend et al., 1970; Mashal et al., 1994;
Hashimoto et al., 1995; Zhang et al., 2006) over-
expression of HMGA2 must not necessarily be
due to mutations affecting the gene itself. It has
recently been described that HMGA2 is regulated
by microRNAs of the let-7 family (Lee and
Dutta, 2007; Mayr et al., 2007; Park et al., 2007;
Shell et al., 2007; Kumar et al., 2008; Motoyama
et al., 2008; Peng et al., 2008). Thus, having now
identiﬁed the overexpression of HMGA2 also in
UL without 12q14-15 alterations being visible at
the microscopic level, future studies should also
address mutations of let-7 genes and their bind-
ing sites within the 30 UTR of HMGA2.
To further validate the cytogenetic results in
cases with high HMGA2 expression and no visible
translocation or vice versa, FISH was performed
with HMGA2 break-apart probes. In the ﬁrst case,
separate signals from BAC clones located 50 and
30 of HMGA2 occurred in 23% of the cells, indi-
cating a translocation with a breakpoint within or
in close proximity of HMGA2. Besides a cryptic
HMGA2 rearrangement undetectable by classical
cytogenetics, a selection of cells without translo-
cation during cell culture may explain the obser-
vation that the karyotype was apparently normal.
However, the fact that chromosome 12 was found
to be aberrant in almost one fourth of the cells
by FISH is concordant with the high HMGA2
expression despite an apparently normal
karyotype.
In the second case showing a low HMGA2
expression despite a visible t(12;14) the signals
Figure 4. FISH with HMGA2 break-apart probes in a UL with
t(12;14)(q15;q24). A: G-banded metaphase prior to FISH. B: The
same metaphase after dual-color FISH indicating a rearrangement of
the HMGA2 locus. C: Corresponding ﬁgure only showing the green
ﬂuorescent probe (RP11-269K4) located proximal (50) to HMGA2. D:
Corresponding ﬁgure only showing the red ﬂuorescent probes
(RP11-745O10 and RP11-293H23) located distal (30) to HMGA2.
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were colocalized in 98% of the cells suggesting
that the breakpoint was localized outside the region
covered by the FISH probes. This unusually large
distance between the breakpoint and HMGA2 may
explain why the observed HMGA2 expression was
unexpectedly low in one UL with a t(12;14). On the
other hand, as indicated by FISH on metaphases of
one UL with t(12;14)(q15;q24), an extragenic
breakpoint upstream but in closer proximity of
HMGA2 can be sufﬁcient to trigger the observed
overexpression. Breakpoints located 50 of HMGA2
in UL with t(12;14) have also been reported by
Quade et al. (2003).
The HMGA2 expression in uterine leiomyomas
has also been quantiﬁed in a study by Gross et al.
(2003). Eleven karyotypically normal UL plus
four matching myometrial samples as well as 10
UL with 12q14-15 rearrangements plus three
myometrial tissues were analyzed by qRT-PCR,
and a signiﬁcantly higher HMGA2 expression in
UL with 12q14-15 rearrangements was noted.
However, in contrast to the present study, no sig-
niﬁcant differences between the expression levels
in karyotypically normal UL and matching myo-
metrial samples were observed.
In summary, our results conﬁrm the strongly
increased HMGA2 expression in UL with 12q14-
15 rearrangements. Moreover, the expression lev-
els detected in 101 UL from 51 patients and 51
matching myometrial samples indicate a general
increase of HMGA2 mRNA also in karyotypically
normal tumors.
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Abstract A subset of uterine leiomyomas (UL) shows chromosomal rearrangements of the region
12q14~q15, leading to an overexpression of the high-mobility group protein A2 gene (HMGA2).
Recent studies identiﬁed microRNAs of the let-7 family as post-transcriptional regulators of
HMGA2. Intragenic chromosomal breakpoints might cause truncated HMGA2 transcripts lacking
part of the 3’ UTR. The corresponding loss of let-7 complementary sites (LCS) located in the 3’
UTR would therefore stabilize HMGA2 mRNA. The aim of this study was to check UL with rear-
rangements of the chromosomal region 12q14~15 for truncated HMGA2 transcripts by real-time
reverse-transcription polymerase chain reaction. In 8/13 leiomyomas with aberrations of chromo-
somal region 12q15, the results showed the presence of the complete 3’ UTR with all LCS. A differ-
ential expression with highly reduced 3’ untranslated region levels was found in 5/13 myomas. In
two of these, full-length transcripts were almost undetectable. Truncated transcripts were apparently
predominant in roughly one-third of UL with chromosomal rearrangements affecting the HMGA2
locus, where they lead to a higher stability of its transcripts and subsequently contribute to the over-
expression of the protein. The assay used is also generally suited to detect submicroscopic alter-
ations leading to truncated transcripts of HMGA2.  2010 Elsevier Inc. All rights reserved.
1. Introduction
A subgroup of uterine leiomyomas (UL) is characterized
by rearrangements of chromosomal segment 12q14~q15.
Roughly 15 years ago, a causal link among these aberra-
tions, the deregulation of the gene encoding the high-
mobility group AT-hook 2 (HMGA2), and the pathogenesis
of UL has been shown [1e3]. HMGA2 was found to be tar-
geted by breakpoints that are located either intragenically
or extragenically 3’ or 5’ of the gene. This type of abnor-
mality is shared by a variety of other mainly benign tumors
of mesenchymal origin (e.g., lipomas or pulmonary chon-
droid hamartomas) [1,2,4,5]. Initially, the transcriptional
deregulation of HMGA2 by the rearrangements of control-
ling elements and/or fusion genes was thought to be the
relevant molecular alteration resulting from the chromo-
somal rearrangements. Because HMGA2 is abundantly
expressed during prenatal development and because its
rearrangements often leave the open reading frame (ORF)
intact, it is tempting to assume that the increased protein
level alone is sufﬁcient to cause or contribute to UL devel-
opment [6]. Accordingly, the 12q14~q15 rearrangements
are always associated with a drastically increased level of
HMGA2 mRNA [7e9]. However, there have been recent
descriptions of another mechanism by which the chromo-
somal deviations can lead to a higher stability of the
HMGA2 transcript and, subsequently, a higher protein level
as well. The 3’ untranslated region (UTR) of HMGA2 was
shown to harbor multiple binding sites for microRNAs of
the let-7 family [10e14]. Truncations of the HMGA2 tran-
script resulting from intragenic breakpoints can thus reduce
the sensitivity of the transcript against microRNAs of the
let-7 family, ﬁnally leading to a higher protein level in
the corresponding cells. This also explains an earlier obser-
vation that constructs containing a truncated HMGA2 3’
UTR are more stable than those with a wild-type UTR
[15]. While this mechanism is experimentally well docu-
mented, it is unclear to which extent truncation of HMGA2
* Corresponding author. Tel.: þ49-421-2184239; fax: þ49-421-
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mRNA coincides with the chromosomal rearrangements of
the gene locus and could amplify the effect of simple tran-
scriptional up-regulation. To address this question, we have
quantiﬁed and compared the level of wild-type and
truncated HMGA2 mRNA from 13 primary UL and 2 cell
lines derived from UL with 12q14~q15 rearrangements
by real-time reverse-transcription polymerase chain reac-
tion (RT-PCR).
2. Materials and methods
2.1. Tumor samples and cell culture
Tissue samples of uterine leiomyomas were collected
immediately after surgery, snap-frozen in liquid nitrogen,
and stored at e80 C for RNA isolation. Samples used
for cell culturing were treated as described previously [9].
Immortalized cells from a lipoma with a t(3;12)
(q27~q28;q14~q15) accompanied by a partial genomic
deletion of the HMGA2 locus were used as a control
because the presence of fusion transcripts consisting of
exons 1e3 of HMGA2 and exons 9e11 of LPP was shown
for this case [16]. Cells were cultured in medium 199 with
Earle’s salts containing 1% fetal calf serum (FCS) for
24 hours and in FCS-free medium for an additional
24 hours to avoid the stimulating effects of FCS on the
expression of HMGA2 from the nonrearranged allele.
Before the isolation of total RNA, cells were lysed directly
in the cell culture ﬂask.
2.2. Methods
Total RNA was isolated from tissue samples and cell
cultures using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). In addition to the on-column DNase I digestion,
a second digestion was performed in solution before reverse
transcription, since the PCR reaction with the primer set
binding in the 3’ UTR of HMGA2 is highly sensitive to
contaminations with genomic DNA.
Reverse transcription of 250 ng RNA was carried out
with Moloney Murine Leukemia Virus (M-MLV) reverse
transcriptase and random hexamers (Invitrogen, Karlsruhe,
Germany) according to the manufacturer’s recommenda-
tions. Controls without enzyme (NoRT) were included for
each sample to ensure the absence of DNA contaminations,
which would introduce a bias to the results of the 3’
UTRespeciﬁc primer set.
Quantitative real-time RT-PCR was performed on a 7300
Real-Time PCR System (Applied Biosystems, Darmstadt,
Germany) with TaqMan Universal PCR Mastermix. Of each
cDNA, 2 mL served as template in a ﬁnal reaction volume of
20 mL. Reaction conditions were as follows: 2 minutes at
50 C, 10 minutes at 95 C, and 50 cycles of 15 seconds at
95 Cand 1 minute at 60 C.A commercialHMGA2-speciﬁc
assay (assay IDHs00171569_m1; Applied Biosystems) with
primers binding in exons 1 and 2 was used to detect tran-
scripts irrespectively of a possible downstream truncation.
In addition, for full-length transcripts with an intact 3’
UTR, a set of primers and probe complementary to the distal
3’ end of the mRNA downstream of all let-7 complementary
sites (Fig. 1) was designed (forward primer: 5’-TGTATTAT
CACTGTCTGTTCTGCACAA-3’, reverse primer: 5’-TGG
AACTGTAACAAAGAGCAGGAA-3’, probe: 6FAM-CAG
CCTCTGTGATCCCCATGTGTTTTG-TAMRA). A differ-
ential expression of full-length and truncated HMGA2 tran-
scripts has been reported recently for lipomas with t(3;12)
[17]. Herein, for evaluating the 3’ UTRespeciﬁc primer/
probe set and graphic display of the results, the same method
with slight modiﬁcations has been used. To evaluate the
primer and probe set designed for the distal 3’ UTR of
HMGA2, a cell line of a lipoma with t(3;12) was tested for
differential expression. In a previous study [16], we had
reported the presence of HMGA2-LPP fusion transcripts
consisting of exons 1e3 of HMGA2 and exons 9e11 of
LPP in this cell line.
HPRT1was chosen as an endogenous control and was de-
tected with the following primer/probe set: forward primer:
5’-GGCAGTATAATCCAAAGATGGTCAA-3’, reverse pri-
mer: 5’-GTCTGGCTTATATCCAACACTTCGT-3’, probe:
6FAM-CAAGCTTGCTGGTGAAAAGGACCCC-TAMRA.
All reactions were run in triplicate. Due to the low HMGA2
expression in normal tissues, the Ct values of the 3’ UTRe
speciﬁc PCR were much higher in myometrial tissues than
in myomas with aberrations affecting the chromosomal
region 12q15, making the use of normal tissue as a calibrator
unsuitable. Therefore, the myoma with the smallest differ-
ence in dCt values between both PCRs (case 4) was chosen
as a calibrator.Although the chromosomal region 12q13~q15
is rearranged in this case, the closely related dCt values
indicate the predominance of full-length transcripts. Thus,
an overestimation of the relative 3’ UTR expression resulting
from the alternative use of myometrial tissues was avoided.
The log10 of the relative expression was used for graphic
display (Fig. 2).
3. Results
In a total of 234 uterine leiomyomas from 124 patients,
chromosome analysis of GTG-banded metaphases revealed
rearrangements of the chromosomal region 12q14~15 in 12
cases (Table 1), which were subjected to real-time RT-PCR
analysis. One additional myoma (case 13) had an appar-
ently normal karyotype, but ﬂuorescence in situ
Fig. 1. Schematic representation of the full-length HMGA2 transcript with
the ORF consisting of ﬁve exons (gray boxes) and let-7 complementary
sites (LCS) in the 3’ UTR (black lines) according to TargetScan [20], PicTar
[21], and miRanda [22,23]. For a detailed list of the LCS, see ref. 11, Table
S2. The black bars below the transcript indicate the positions of the regions
ampliﬁed with two different primer sets.
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hybridization (FISH) revealed split signals for HMGA2,
indicating a hidden rearrangement of the gene locus.
With the criteria deﬁned by Bartuma et al. [17] (i.e., an
expression level that is 10 times higher for exons 1 and 2
than for the distal 3’ UTR), a differential expression was
observed in two myoma cell lines (cases 1 and 2), as well
as in 5/13 myomas (cases 8, 10, 13, 14, and 15; Fig. 2).
In contrast, no differential expression was detected in the
remaining eight myomas.
In the lipoma cell line, whichwas used as control, the rela-
tive expression of HMGA2 exons 1e2 was only slightly
lower than in the myoma used as the calibrator, but the
expression of the distal 3’ UTR is clearly reduced
(log1053,36), thus indicating the usefulness of the test
procedure used.
4. Discussion
We recently reported an overexpression of HMGA2 in
uterine leiomyomas with a normal 46,XX karyotype in
comparison to matching myometrial tissues [9]. Moreover,
our results conﬁrmed the previous ﬁnding, that HMGA2 is
strongly overexpressed in leiomyomas with chromosomal
aberrations, affecting the locus of the gene [7e9]. However,
the molecular mechanisms causing an overexpression,
especially in those cases with cytogenetically detectable
translocations with breakpoints in or close to chromosomal
region 12q14~15, remain to be identiﬁed. Several studies
[10e13] have reported the post-transcriptional regulation
of HMGA2 expression by miRNAs of the let-7 family.
Reduced expression of let-7 family members in uterine
Fig. 2. Relative expression of HMGA2 in uterine leiomyomas with chromosomal aberrations affecting region 12q14~15 and a lipoma cell line with known
absence of full-length transcripts as a control. The log10 of the relative expression levels is shown (RQ: relative quantiﬁcation). qRT-PCR was performed with
primers located in exons 1 and 2 of HMGA2 (light gray bars) and an additional set of primers located in the distal 3’ UTR of the gene (dark gray bars). Case 4
was used as calibrator. Asterisks indicate cell lines of myomas with t(12;14).
Table 1
Karyotypes of 13 leiomyomas and two cell lines (nos. 1 and 2) originating from myomas with chromosomal translocations affecting region 12q13~q15
Case no. Karyotype Age (yr) Tumor diameter (cm)
1 46,XX,del(7)(q22q32),t(12;14)(q15;q24)[29] e e
2 46,X,t(X;12)(q22;q15)[8] e e
3 46,XX,t(12;15;14)(q15;q26;q24)[20]/46,XX[1] 49 1.5
4 46,XX,t(3;5;12)(q23~25;p13~15;q13~15)[11]/45,XX,idem,e22[10] 42 5.0
5 46,XX,der(7)del(7)(p)del(7)(q),add(8)(q2?),add(10)(q2?),t(12;14)(q15;q24)[15] 40 8.0
6 46,XX,t(12;14)(q15;q24)[9]/46,XX[3] 47 5.0
7 46,XX,r(1),t(1;12;14)(p36.3;q14;q24)[7] 40 6.0
8 46,XX,t(2;12)(q33;q13)[17] 49 10.0
9a n. a. 46 3.0
10 46,XX,t(12;14)(q15;q24)[12]/
45,XX,der(1),?t(1;2),e2,add(7)(?q36),t(12;14)(q15;q24)[2]/
46,XX,del(4)(q31~q32),der(10),?t(10,14)(q24;q32),t(12;14)(q15;q24)[9]
47 4.0
11 46,XX,t(12;14)(q15;q24)[5]/46,XX[9] 37 7.0
12 45,XX,t(12;14)(q15;q24),der(14)t(12;14)(q15;q24),e22[8] 32 10.0
13a 46,XX 48 1.5
14 46,XX,t(12;14)(q15;q24)[13]/46,XX,der(1)r(1;2),t(12;14)(q15;q24)[4] 44 6.0
15 46,XX,ins(14;12)[8]/46,idem,r(1)[4] 73 2.5
Abbreviation: n.a., not available
a Case in which FISH revealed split signals for the HMGA2 locus, indicating a rearrangement of the gene.
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leiomyomas has been reported as well [14]. In addition to
a downregulation of miRNAs responsible for the repression
of HMGA2 expression, losses of the let-7 complementary
sites (LCS) within the 3’ UTR of HMGA2 may also lead
to a deﬁciency in let-7emediated regulation [10]. Herein,
we have investigated 13 leiomyomas as well as two cell
lines of myomas with chromosomal aberrations affecting
the HMGA2 locus using a real-time RT-PCR approach to
detect the truncation of HMGA2 transcripts.
In 8/13 myomas, no differential expression between
HMGA2 exons 1 and 2 and the 3’ UTRwas observed (Fig. 2).
This is in good agreement with previous studies reporting
breakpoints upstream of the HMGA2 gene in leiomyomas
with rearrangements of chromosomal region 12q14~15 [18].
A lipoma with a t(3;12)(q27~q28;q14~q15) and a known
disruption of the HMGA2 gene was used as a control. The
observed expression of the 3’ UTR is extremely low in this
sample, indicating the near absence of full-length tran-
scripts. A complete absence should lead to negative PCR
results, however, the negligible expression level is likely
to be caused by a minor transcription of the unaltered allele.
Both cell lines as well as 5/13 myomas revealed a differ-
ential expression of exons 1e2 and the 3’ UTR. In three of
these tumors (cases 10, 14, and 15), however, a noteworthy
amount of transcripts is truncated, but since full-length
transcripts do not seem to be absent, the chromosomal
breakpoint is unlikely to be located within the gene.
Two myomas (nos. 8 and 13) revealed expression levels
of the 3’ UTR, which are comparably low as the 3’ UTR
expression in the control, indicating the almost complete
absence of full-length transcripts. Of note, the karyotype
of one of these cases (no. 13) is apparently normal, but
FISH performed on interphase nuclei indicated a rearrange-
ment of HMGA2 [9].
Overall, the test seems to be well suited to detect trun-
cated HMGA2 transcripts caused by cytogenetically visible
genomic rearrangements as well as by those undetectable
by conventional cytogenetics.
In conclusion, we were able to identify ﬁve leiomyomas
with a strongly reduced expression of the full-length
mRNA, which is the prevailing transcript in the remaining
eight leiomyomas, also showing chromosomal rearrange-
ments affecting 12q14~q15. Thus, a loss of let-7 comple-
mentary sites does not account for the overexpression of
HMGA2 in the majority of UL, but seems to amplify the
effects of a transcriptional de-regulation of HMGA2 in
a rather small subset of these tumors. Of note, phenotypic
effects of a truncation of the HMGA2 3’ UTR have also
been described in a boy with a pericentric inversion of
chromosome 12 that truncated HMGA2 [19].
Acknowledgments
This study was supported by a grant from the To¨njes-
Vagt-Foundation.
References
[1] Ashar HR, Fejzo MS, Tkachenko A, Zhou X, Fletcher JA,
Weremowicz S, Morton CC, Chada K. Disruption of the architectural
factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to
distinct transcriptional regulatory domains. Cell 1995;82:57e65.
[2] Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den
Berghe H, Van de Ven WJ. Recurrent rearrangements in the high
mobility group protein gene, HMGI-C, in benign mesenchymal
tumours. Nat Genet 1995;10:436e44.
[3] Hennig Y, Wanschura S, Deichert U, Bartnitzke S, Bullerdiek J.
Rearrangements of the high mobility group protein family genes
and the molecular genetic origin of uterine leiomyomas and endome-
trial polyps. Mol Hum Reprod 1996;2:277e83.
[4] Kazmierczak B, Rosigkeit J, Wanschura S, Meyer-Bolte K, Van de
Ven WJ, Kayser K, Krieghoff B, Kastendiek H, Bartnitzke S,
Bullerdiek J. HMGI-C rearrangements as the molecular basis for
the majority of pulmonary chondroid hamartomas: a survey of 30
tumors. Oncogene 1996;12:515e21.
[5] Wanschura S, Kazmierczak B, Pohnke Y, Meyer-Bolte K,
Bartnitzke S, Van de Ven WJ, Bullerdiek J. Transcriptional activa-
tion of HMGI-C in three pulmonary hamartomas each with
a der(14)t(12;14) as the sole cytogenetic abnormality. Cancer Lett
1996;102:17e21.
[6] Klotzbu¨cher M, Wasserfall A, Fuhrmann U. Misexpression of wild-
type and truncated isoforms of the high-mobility group I proteins
HMGI-C and HMGI(Y) in uterine leiomyomas. Am J Pathol 1999;
155:1535e42.
[7] Hennig Y, Rogalla P, Wanschura S, Frey G, Deichert U, Bartnitzke S,
Bullerdiek J. HMGIC expressed in a uterine leiomyoma with a dele-
tion of the long arm of chromosome 7 along with a 12q14-15 rear-
rangement but not in tumors showing del(7) as the sole cytogenetic
abnormality. Cancer Genet Cytogenet 1997;96:129e33.
[8] Gross KL, Neskey DM, Manchanda N, Weremowicz S,
Kleinman MS, Nowak RA, Ligon AH, Rogalla P, Drechsler K,
Bullerdiek J, Morton CC. HMGA2 expression in uterine leiomyoma-
ta and myometrium: quantitative analysis and tissue culture studies.
Genes Chromosomes Cancer 2003;38:68e79.
[9] KlemkeM,Meyer A. Hashemi NezhadM, Bartnitzke S, Drieschner N,
Frantzen C, Schmidt EH, Belge G, Bullerdiek J. Overexpression of
HMGA2 in uterine leiomyomas points to its general role for the path-
ogenesis of the disease. Genes Chromosomes Cancer 2009;48:171e8.
[10] Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7
and Hmga2 enhances oncogenic transformation. Science 2007;315:
1576e9.
[11] Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses
the HMGA2 oncogene. Genes Dev 2007;21:1025e30.
[12] Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA,
Feig C, Lengyel E, Peter ME. Let-7 expression deﬁnes two differen-
tiation stages of cancer. Proc Natl Acad Sci USA 2007;104:11400e5.
[13] Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B,
Dinulescu DM, Lengyel E, Peter ME. Let-7 prevents early cancer
progression by suppressing expression of the embryonic gene
HMGA2. Cell Cycle 2007;6:2585e90.
[14] Peng Y, Laser J, Shi G, Mittal K, Melamed J, Lee P, Wei JJ. Antipro-
liferative effects by let-7 repression of high-mobility group A2 in
uterine leiomyoma. Mol Cancer Res 2008;6:663e73.
[15] Borrmann L, Wilkening S, Bullerdiek J. The expression of
HMGA genes is regulated by their 3 ’UTR. Oncogene 2001;20:
4537e41.
[16] Lemke I, Rogalla P, Bullerdiek J. Large deletion of part of the
HMGIC locus accompanying a t(3;12)(q27~q28;q14~q15) in a
lipoma. Cancer Genet Cytogenet 2001;129:161e4.
[17] Bartuma H, Panagopoulos I, Collin A, Trombetta D, Domanski HA,
Mandahl N, Mertens F. Expression levels of HMGA2 in adipocytic
tumors correlate with morphologic and cytogenetic subgroups. Mol
Cancer 2009;8:36.
122 M. Klemke et al. / Cancer Genetics and Cytogenetics 196 (2010) 119e123
[18] Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C. Dal Cin P,
Morton CC. Fusion transcripts involving HMGA2 are not a common
molecular mechanism in uterine leiomyomata with rearrangements in
12q15. Cancer Res 2003;63:1351e8.
[19] Ligon AH, Moore SD, Parisi MA, Mealiffe ME, Harris DJ,
Ferguson HL, Quade BJ, Morton CC. Constitutional rearrangement
of the architectural factor HMGA2: a novel human phenotype
including overgrowth and lipomas. Am J Hum Genet 2005;76:
340e8.
[20] Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB.
Prediction of mammalian microRNA targets. Cell 2003;115:787e98.
[21] Krek A, Gru¨n D, Poy MN, Wolf R, Rosenberg L, Epstein EJ,
MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N.
CombinatorialmicroRNA target predictions. NatGenet 2005;37:495e500.
[22] John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human
MicroRNA targets. PLoS Biol 2004;2:e363.
[23] Betel D,WilsonM, GabowA,Marks DS, Sander C. ThemicroRNA.org
resource: targets and expression.NucleicAcids Res 2008;36:D149e53.
123M. Klemke et al. / Cancer Genetics and Cytogenetics 196 (2010) 119e123
III
HMGA2 and the p19Arf-TP53-CDKN1A axis: A delicate balance in the growth of
uterine leiomyomas
Dominique Nadine Markowski, Inga von Ahsen, Maliheh Hashemi Nezhad, Werner
Wosniok, Burkhard Maria Helmke,  Jörn Bullerdiek.
Genes, Chromosomes & Cancer, (2010), 49: 661-668
Own contribution:
Conventional cytogenetics
GENES, CHROMOSOMES & CANCER 49:661–668 (2010)
HMGA2 and the p19Arf-TP53-CDKN1A Axis:
A Delicate Balance in the Growth of
Uterine Leiomyomas
Dominique Nadine Markowski,1,2 Inga von Ahsen,2 Maliheh Hashemi Nezhad,1 Werner Wosniok,3
Burkhard Maria Helmke,4† and Jo¨rn Bullerdiek1,2*
1Centerof Human Genetics,Universityof Bremen,Leobener Strasse ZHG, 28359 Bremen,Germany
2Small Animal Clinic,Universityof Veterinary Medicine and Research Clusterof Excellence‘‘REBIRTH’’, 30173 Hannover,Germany
3Institute of Statistics,Universityof Bremen, 28359 Bremen,Germany
4Institute of Pathology,Universityof Heidelberg,69120 Heidelberg,Germany
Pathogenetically, uterine leiomyomas (ULs) can be interpreted as the result of a monoclonal abnormal proliferation of
myometrial cells. Oncogene-induced senescence (OIS) is a frequent phenomenon in premalignant lesions that leads to a
growth arrest mainly by the activation of two potent growth-inhibitory pathways as represented by p16Ink4a and p19Arf.
The relevance of OIS for the development of UL has not been addressed, but HMGA2, encoded by a major target gene
of recurrent chromosomal abnormalities in UL, has been implicated in the repression of the Ink4a/Arf (CDKN2A) locus.
This prompted us to examine if HMGA2 contributes to the growth of leiomyomas by repressing this locus. Contrary to
the expectations, we were able to show that generally ULs express signiﬁcantly higher levels of p19Arf mRNA than
myometrium and that UL with 12q1415 rearrangements showed higher expression levels than UL with other cytogenetic
aberrations. Furthermore, the ﬁnding of a signiﬁcant correlation between the expressions of p19Arf and CDKN1A shows
that p19Arf triggers senescence rather than apoptosis in UL. Furthermore, the expression levels of HMGA2, p19Arf, and
CDKN1A were found to be correlated with the size of the tumors, indicating that an enhanced growth potential is counter-
balanced by the p19Arf pathway. Mechanistically, the UL may thus execute a program already present in their cell of origin,
where it is activated to protect the genome, for example, in the case of enhanced proliferation. In summary, the results
identify the p19Arf-TP53-CDKN1A pathway as a major player in the growth control and genomic stability of uterine
ﬁbroids. VC 2010 Wiley-Liss, Inc.
INTRODUCTION
Uterine leiomyomas (ULs) are benign smooth
muscle tumors with a high prevalence, making
them the most frequent gynecological tumors. On
the basis of histology and ultrasound studies, it
has been estimated that up to 70–80% of women
in their reproductive age have one or more
leiomyomas (Cramer and Patel, 1990; Baird et al.,
2003). Symptomatic leiomyomas are a major
public health problem, accounting for 30% of
all hysterectomies in the United States (Sand-
berg, 2005). Still, relatively little is known about
the pathogenesis and etiology of UL. Although
numerous hypotheses have been put forward to
explain the development of UL (for review, see
Sandberg, 2005), their monoclonal origin suggests
mutations as the leading cause of abnormal prolif-
eration of the leiomyoma cells because consistent
mutations observed in considerable fractions of
UL chromosomal aberrations dominate (for
review see Ligon and Morton, 2000; Sandberg,
2005). A large subgroup of UL is characterized by
clonal translocations affecting chromosomal
region 12q1415, leading to upregulation of
HMGA2 (Schoenmakers et al., 1995; Gross et al.,
2003; Klemke et al., 2009). Interestingly, ULs
with 12q1415 rearrangements are larger than
those without detectable cytogenetic deviations
(Rein et al., 1998; Hennig et al., 1999). Although
it is tempting to speculate that the overexpres-
sion of HMGA2, a protein abundantly expressed
in stem cells and linked to their self-renewal (Li
et al., 2006, 2007; Nishino et al., 2008), accounts
for that enhanced growth potential, the exact
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mechanisms by which HMGA2 can inﬂuence UL
growth still remain to be resolved. Recently, a
link between HMGA2 and the CDKN2A locus
(encoding p16Ink4a and p19Arf) was reported for
somatic stem cells. Expression of that locus is
associated with the control of cellular senescence
in many cell types and was found to be repressed
by HMGA2 (Nishino et al., 2008). Accordingly, it
can be speculated that repression of the CDKN2A
locus by the abundance of HMGA2 accounts for
the larger size of UL with HMGA2 rearrange-
ments compared with those without that muta-
tion (Rein et al., 1998; Hennig et al., 1999). By
immunohistochemistry, p16Ink4a positivity was
found more often in leiomyosarcomas than in
leiomyomas, where it appears to be restricted to
single cases only (Atkins et al., 2008; Lee et al.,
2009), but in-depth studies addressing the expres-
sion of Ink4a/Arf and the genes of their corre-
sponding pathways have not been performed in
different genetic subtypes of UL.
Herein, we have investigated a series of ULs
with 12q1415 rearrangements and other aberra-
tions for their expression of p16Ink4a and p19Arf.
MATERIALS AND METHODS
Tissue Samples and Cells
Samples of ULs and myometrium were taken
during surgery, immediately frozen in liquid
nitrogen, and stored at 80C for RNA isolation.
As a reference for the expression of the CDKN2A
locus, human adipose tissue–derived stem cells
(ADSCs) isolated from subcutaneous adipose tis-
sue were used. Subcutaneous adipose tissue was
taken during surgery from patients admitted to
the Department of General and Vascular Surgery,
Clinical Center Bremen-Nord, Bremen, Germany.
For cell culture, the tissue was transferred into
sterile Hank’s solution and minced into small
pieces followed by a treatment with 0.26% (200
U/ml) collagenase (Serva, Heidelberg, Germany).
After 1–2 hr, the dissociated cells were trans-
ferred into sterile 25-cm2 cell culture ﬂasks con-
taining 5-ml medium 199 supplemented with
20% fetal bovine serum (FBS) (Invitrogen,
Karlsruhe, Germany) and antibiotics (2% penicil-
lin–streptomycin; Biochrom, Berlin, Germany).
The cultures were incubated in 5% CO2 air at
37C, and medium was changed every 2–3 days.
Cultures were passaged when reaching 80% con-
ﬂuence using 1 concentrated TrypLE Express
in a PBS-EDTA buffer. The cells were subcul-
tured in medium 199 with 10% FBS and
antibiotics.
RNA Isolation
Total RNA was isolated from frozen tissue
samples and from cell cultures by using the miR-
Neasy Mini Kit (Qiagen, Hilden, Germany), and
DNase I digestion was performed following the
manufacturer’s instructions.
cDNA Synthesis
Two hundred and ﬁfty nanograms of total
RNA was reverse transcribed with M-MLV
reverse transcriptase (Invitrogen, Karlsruhe,
Germany), RNase Out (Invitrogen, Karlsruhe,
Germany), random hexamers, and dNTPs accord-
ing to the manufacturer’s instructions. RNA was
denatured at 65C for 5 min and subsequently
kept on ice for 1 min. After adding the enzyme
to the RNA primer mixes, samples were incu-
bated for 10 min at 25C to allow annealing of
the random hexamers. Reverse transcription was
performed at 37C for 50 min followed by inacti-
vation of the reverse transcriptase at 70C for
15 min.
Quantitative Real-Time PCR
Relative quantiﬁcation of transcription levels
was carried out by real-time PCR analyses using
the Applied Biosystems 7300 Real-Time PCR
system (Applied Biosystems, Darmstadt, Ger-
many). Relative mRNA levels of HMGA2, p19Arf,
p16Ink4a, CDKN1A, MDM2, and MKI67 were deter-
mined by relative quantiﬁcation referring to the
expression of the housekeeping gene HPRT,
which turned out to be expressed steadily in
our own experiments on leiomyomas and myome-
trial tissue. For quantiﬁcation, the assays
Hs00924091_m1 (p19Arf), Hs00923893_m1 (p16Ink4a),
Hs00171569_m1 (HMGA2), Hs99999142_m1
(CDKN1A), Hs01066930_m1 (MDM2), and
Hs00606991_m1 (MKI67) (Applied Biosystems,
Darmstadt, Germany) were used. Primers and
probe used to amplify HPRT were the same as
those previously described by Specht et al. (2001).
All experiments were done in triplicate.
RESULTS
First, 36 ULs and eight myometrial tissues
were tested by qRT-PCR for their expression of
p16Ink4a and p19Arf mRNA. Although the control
662 MARKOWSKI ET AL.
Genes, Chromosomes & Cancer DOI 10.1002/gcc
(ADSCs, sixth in vitro passage) but none of the
samples showed a detectable expression of
p16Ink4a mRNA, p19Arf mRNA was detectable in
all samples, in the same range as in the ADSCs
(Fig. 1). On the basis of the cytogenetic analyses,
the leiomyomas were further divided into a group
with 12q1415 aberrations (n ¼ 20), a group with
normal karyotypes (n ¼ 10), and a group with other
clonal cytogenetic aberrations (n ¼ 6). Generally,
the expression of p19Arf varied over a broad range
in UL, whereas it was almost identical in the myo-
metrial tissues. The relative p19Arf mRNA expres-
sion in the UL signiﬁcantly (P < 0.01) exceeded
that in myometrial tissue by more than 12-fold
with an average p19Arf mRNA level of 1.303
(range: 0.182–2.119) in myometrial tissue and
16.199 (range: 0.701–74.829) in ULs. Furthermore,
in UL with 12q1415 aberrations, p19Arf mRNA
was expressed at higher levels than in UL with
normal karyotypes (21.604 vs. 9.633, P < 0.05).
Comparing the p19Arf expression of UL with
12q1415 aberrations with myometrial tissue
resulted in a 16.6-fold (P < 0.01) higher expression
in the aberrant leiomyomas. Because these ﬁndings
suggest HMGA2 as an agonist of the p19Arf-TP53
pathway, we reasoned that this pathway may be a
major player in controlling the growth of UL.
Enhanced levels of TP53 can either induce
apoptosis or an irreversible growth arrest, that is,
senescence. Although previous data (Dixon et al.,
2002) excluded apoptosis as a prominent feature of
UL based on the analyses of the apoptosis-
regulating proteins BCL2 and BAX, overexpression
of b-galactosidase in UL compared with matching
myometrium points to a possible signiﬁcance of se-
nescence. Accordingly, we analyzed if the expres-
sion of CDKN1A, a direct target of transcriptional
regulation by TP53 within the senescence route, is
positively correlated with the expression of p19Arf.
For these analyses, only 19 ULs with 12q1415
rearrangements and 10 with an apparently normal
karyotype were used. A strongly positive linear cor-
relation between the two mRNAs was noted (P <
0.001; Fig. 2). Similar to what was found for p19Arf,
ULs with 12q1415 rearrangements expressed
higher (P < 0.05) levels of p21 mRNA than those
with an apparently normal karyotype. Next, we
examined if the expression of HMGA2, p19Arf, and
CDKN1A correlates with the size of the UL. For
these analyses, data on 24 ULs, including nine with
an apparently normal karyotype and 15 with
12q1415 rearrangements, were available. For all
the three genes, a positive correlation with the size
of the UL was noted (Fig. 3). In contrast, none of
them showed any correlation with proliferation, as
indicated by the expression of MKI67 mRNA (data
not shown). Because a positive feedback loop
between TP53 and MDM2 is well documented, we
Figure 1. Relative quantiﬁcation of the p19Arf expression in uterine leiomyomas and myometrial tis-
sues. Grey bars: myometrium; white bars: UL with normal karyotype; black bars: UL with 12q1415
aberrations; hatched bars: UL with other clonal cytogenetic aberrations, checkered bar: ADSCs (6th pas-
sage). Myometrial tissue served as calibrator (expression: 1).
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were interested to analyze if enhanced expression
of p19Arf triggers an increased expression of MDM2
as well. A highly signiﬁcant linear correlation (P <
0.001) between the expressions of p19Arf and
MDM2 was noted (Fig. 4). Moreover, ﬁbroids with
12q1415 rearrangements expressed signiﬁcantly
(P < 0.05) higher levels of MDM2 mRNA than
those with an apparently normal karyotype.
Figure 3. Signiﬁcant linear correlations between the expression of HMGA2, p19Arf, and CDKN1A (y
axis, %), respectively, and the size of ﬁbroids investigated. For the expression of all the three genes, the
tumor with the highest expression each is adjusted to 100%.
Figure 2. Correlation between the relative CDKN1A expression (x axis) and the relative p19Arf
expression (y axis) in myometrium (~), UL with 12q1415 aberrations (l), and UL with a normal
karyotype (^). Myometrial tissue served as calibrator (expression: 1).
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DISCUSSION
ULs are highly frequent benign tumors of
women in their reproductive age. In numerous
studies, the inﬂuence of the hormonal environ-
ment as well as, for example, gene polymor-
phisms, epigenetics, a familial disposition, or
even oncogenic viruses (Romagnolo et al., 1996;
Webster et al., 1998; Bullerdiek, 1999; Asada
et al., 2008) and recently the deregulation of
micro-RNA genes (Luo and Chegini, 2008; Marsh
et al., 2008; Wei and Soteropoulos, 2008) have
been considered as factors related to the develop-
ment of these tumors. Fibroids are clonally aris-
ing from the proliferation of smooth muscle cells
(SMCs) or their progenitors. Nevertheless,
although cytogenetic analyses allow to distinguish
between different cytogenetic subtypes of ULs
and point to genes of pathogenetic relevance for
the disease, generally, very little is known about
downstream mechanisms linked to its pathogene-
sis. In one of these cytogenetic subtypes, rear-
rangements of the chromosomal region 12q1415
lead to an upregulation of HMGA2 expression.
Recent data suggesting a relationship between
the expression of HMGA2 and the repression of
the senescence-associated proteins encoded by
the CDKN2A locus (Nishino et al., 2008)
prompted us to examine if HMGA2 exerts at
least in part its stimulation of SMC growth by
repression of their senescence program. Contrary
to expectations, uterine ﬁbroids generally
expressed one gene of the CDKN2A locus, that is,
p19Arf, at signiﬁcantly higher levels than normal
myometrium. In contrast, no such differences
were noted for p16Ink4a, the other gene of the
locus. The two proteins encoded by the CDKN2A
locus, that is, p16Ink4a and p19Arf, are cell cycle
inhibitors that both have been linked to cellular
senescence. Of these, p16Ink4a blocks phosphoryl-
ation and inactivation of the retinoblastoma
protein (RB1), whereas p19Arf blocks the ubiqui-
tylation and degradation of TP53 via its interac-
tion with MDM2 (Zhang et al., 1998; Meek,
2009). In primary ﬁbroblasts, p19Arf seems to
mediate a network that enforces Ras-induced cell
cycle arrest and tumor suppression (Sebastian and
Johnson, 2009). Upregulation of p19Arf is part of
oncogene-induced senescence (OIS), a term
coined to indicate a form of senescence resulting
from activated oncogenes and oncogenic viruses.
Besides being part of the TP53 network, p19Arf is
also known to have TP53-independent antiproli-
ferative activities. Mice lacking p19Arf, MDM2,
and TP53 in combination develop a much broader
spectrum of tumors than animals lacking p19Arf or
TP53 alone. The tumors arise rapidly and can
appear simultaneously at independent sites,
where they can involve mesenchymal, epithelial,
Figure 4. Correlation between the relative MDM2 expression (x axis) and the relative p19Arf expres-
sion (y axis) in myometrium (~), UL with 12q1415 aberrations (l), and UL with a normal karyotype
(^). Myometrial tissue served as calibrator (expression: 1).
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hematopoietic, or neural cells, suggesting that the
p19Arf-MDM2-TP53 pathway is not strictly linear
(Lowe and Sherr, 2003).
Generally, both proteins of the CDKN2A locus
have been implicated in the suppression of neo-
plastic growth, and the CDKN2A locus is among
the most frequently inactivated gene loci in
human cancers (Lowe and Sherr, 2003). Mice car-
rying a targeted deletion of the CDKN2A locus
eliminating both p16Iin4a and p19Arf develop spon-
taneous tumors at an early age and are highly
sensitive to carcinogenic treatments (Serrano
et al., 1996). In line with these ﬁndings, it has
recently been shown that cells with low endoge-
nous p19Arf levels and immortal ﬁbroblasts deﬁ-
cient in components of the p19Arf-TP53 pathway
yield induced pluripotent stem cell colonies with
up to threefold faster kinetics and at a signiﬁ-
cantly higher efﬁciency than wild-type cells (Uti-
kal et al., 2009).
Our results show that in UL, a stimulation of
the p19Arf axis rather leads to senescence than to
apoptosis as revealed by an overexpression of
CDKN1A.
However, the balance between proliferation
and senescence seems to be in a delicate balance,
and the correlation between p19Arf and MDM2
suggests an oscillation between both gene activ-
ities, which has been described to result from a
positive TP53-MDM2 feedback loop (Proctor
and Gray, 2008; Jolma et al., 2010). As to the de-
velopment of UL, the higher expression of p19Arf
may thus account for the unexpectedly lower in-
herent ex vivo growth potential of UL cells com-
pared with myometrial cells (Carney et al., 2002;
Loy et al., 2005; Chang et al., 2010) as well as to
the higher rate of b-galactosidase-positive cells
(Dixon et al., 2002). Simultaneously, Chang et al.
(2010) were also able to demonstrate that UL
exhibited fewer stem and progenitor cell charac-
teristics, respectively, than matching myome-
trium. Generally, the presence of a stem cell–like
population in the myometrium has been postu-
lated and, for example, been linked to changes of
uterine smooth muscle tissue during postpartum
involution (Shynlova et al., 2009). Accordingly, a
study by Ono et al. (2007) revealed the existence
of a stem cell–like side population of quiescent
multipotent human myometrial cells, which they
referred to as myoSP cells. On the basis of these
ﬁndings, they have suggested that repeated men-
struation-induced hypoxia may cause clonal pro-
liferation of a myoSP cell that would ultimately
result in the development of a UL, which as a
secondary event can acquire cytogenetic abnor-
malities. This hypothesis traces back the origin of
ULs to initially multipotent stem cells and is in
line with the multilineage differentiation occa-
sionally seen in UL, that is, lipoleiomyoma or
chondroleiomyoma.
However, the highly signiﬁcant upregulation of
p19Arf and CDKN1A in UL offers prima facie sup-
porting data explaining their lower in vitro growth
potential compared with normal tissue and does
neither exclude a stem cell origin of UL nor con-
tradict the loss of stem cell characteristics. In
addition, the fact that fewer stem cell colonies
are formed from tissue taken from UL than from
myometrium (Chang et al., 2010) may be due to
advanced senescence and ﬁts with the correlation
between p19Arf and CDKN1A mRNA expression
found in this study.
In Figure 5, available data on the relevant
pathway are summarized. The cell of UL origin
may be a myoSP cell or a more differentiated cell
where an unknown oncogenic event is supposed
to trigger a mild form of OIS leading to an upreg-
ulation of p19Arf compatible with slow clonal pro-
liferation. In the subset of UL with chromosomal
rearrangements of 12q1415, the drastically up-
regulated HMGA2 expression can induce or
strengthen the OIS in a dose-dependent manner.
Second, the expression of p19Arf and the corre-
sponding pathway increases with the growth of
the tumor cell population as reﬂected by the cor-
relation between p19Arf and CDKN1A mRNA
with tumor size. Overall, the induction of this
pathway as well as of the positive feedback loop
involving MDM2 may be a reminiscence of the
stem cell origin of uterine ﬁbroids and may help
the tumor cells to maintain their genomic integ-
rity despite high levels of HMGA2. Finally, we
feel that the interplay between HMGA2 and
p19Arf/CDKN1A, which apparently, among other
factors, depends on the degree of overexpression
of HMGA2, seems to be one of the key elements
determining the ﬁnal size of UL. Interestingly,
OIS was also recently considered as a cause for
the spontaneous cessation of growth of pituitary
adenomas (Mooi, 2009), benign endocrine tumors
that share with leiomyomas the frequent upregu-
lation of HMGA2 (Fedele and Fusco, in press).
In summary, OIS governed by the p19Arf-p21
axis seems to be an important phenomenon in
the development of UL and cessation of their
growth. HMGA2, encoded by a gene targeted in
a frequent genetic subtype of UL, and the senes-
cence-associated p19Arf and p21 are assumed to
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be the major players interacting in different ways
to dictate the fate of an individual UL.
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Abstract To quantify the expression of HMGA1mRNA in uterine leiomyomas, the expression of HMGA1 was
analyzed in a series including tumors with aberrations of chromosome 6 (n5 7) and cytogenetically
normal tumors (n5 8) as a control group by quantitative reverse transcriptaseepolymerase chain reac-
tion. The average expression level in the 6p21 group was found to be 5.6 times higher than that in the
control group, and with one exception, all cases with 6p21 alteration revealed a high expression of
HMGA1mRNAthan cytogenetically normal tumors.Nevertheless, compared toﬁbroidswith a normal
karyotype, the upregulation of the HMGA1 mRNA in these cases was much less strong than that of
HMGA2 mRNA in case of 12q14~15 aberrations identiﬁed in previous studies.  2010 Elsevier
Inc. All rights reserved.
1. Introduction
Uterine leiomyomas (ULs) belong to the cytogenetically
best investigated human tumors. The cytogenetic analyses
have revealed several subtypes, with a frequent group
showing rearrangements of chromosomal region 12q14~15,
which apparently targets the gene encoding the high-
mobility group AT-hook 2 (HMGA2) [1,2]. Accordingly,
tumors of this type show signiﬁcantly higher expression of
HMGA2 than ﬁbroids with an apparently normal karyotype
[3]. HMGA2 is a protein abundantly expressed in stem cells
and casually linked to their self-renewal ability.A decrease of
HMGA2 has recently seen linked to the group of hematopoi-
etic as well as neural stem cells [4]. Accordingly, it is
tempting to speculate that in terms of pathogenesis, smooth
muscle cells continuously expressing HMGA2 are maintain-
ing a self-renewing program that occasionally also display
multilineage potential as witnessed by variants as, for
example, lipoleiomyomas or leiomyomas with cartilaginous
differentiation [5,6].
Of note, a smaller subgroup of ULs shows rearrange-
ments of 6p21 (i.e., the locus where HMGA1, the other
gene encoding proteins of the HMGA type, has been
mapped), suggesting that HMGA1 is the relevant target
gene in that subgroup of ULs [7]. In small series of ULs,
it was shown that this rearrangement leads to an overex-
pression of HMGA1 [8,9]. However, to our knowledge, no
study quantifying the expression of HMGA1 mRNA in
ULs of this subtype has been performed. Thus, we analyzed
the HMGA1 expression in seven ULs with aberrations of
chromosome 6 in comparison to myomas with normal
karyotype and to the matching myometrial tissues.
2. Materials and methods
2.1. Tissue samples and chromosome analysis
For RNA isolation, samples of ULs and myometrium
were snap frozen in liquid nitrogen immediately after
surgery and stored at 80C. For cell culture, samples of
primary tumors were transferred to Hank’s solution with
antibiotics (200 IU/mL penicillin, 200 mg/mL strepto-
mycin) after surgery. Cell culture and chromosome anal-
yses were performed as described previously [3].
2.2. RNA isolation, reverse transcription, and quantitative
reverse transcriptaseepolymerase chain reaction
Total RNA was isolated from tissue samples with the
RNeasy Mini Kit (Qiagen, Hilden, Germany) including
* Corresponding author. Tel.: þ49-421-2184239; fax: þ49-421-
2184239.
E-mail address: bullerd@uni-bremen.de (J. Bullerdiek).
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DNase 1 treatment according to the manufacturer’s instruc-
tions, and quantitated by spectrophotometry. Reverse
transcription of 250 ng RNA was carried out with
M-MLV reverse transcriptase, RNaseOUT, and random
hexamers (Invitrogen, Karlsruhe, Germany) according to
the manufacturer’s recommendations. Controls without
reverse transcriptase were included for each sample to
ensure the absence of DNA contaminations, which, as
a result of the high number of HMGA1-related retropseudo-
genes, could lead to false-positive results.
Quantitative real-time reverse transcriptaseepolymerase
chain reaction (RT-PCR) was performed on a real-time
Fig. 1. Karyotypes of two ULs with 6p21 rearrangements with different levels of HMGA1 expression and the histologic appearance of these ULs. (A) Repre-
sentative G-banded karyotype of myoma 87: 46,XX,t(6;14)(p23;q24), tas(14;21)(pter;qter). (B) Representative G-banded karyotype of myoma 125A: 46,XX,
t(6;11)(p21;p15), chromosomes participating in the 6p21 rearrangements are indicated by arrows. Histologic appearance of myoma 87 (C) and myoma
125A (D).
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PCR cycler (Applied Biosystems, Darmstadt, Germany)
with TaqMan Universal Mastermix. Of each cDNA, 2 mL
served as template in a ﬁnal reaction volume of 20 mL.
Reaction condition were as follows: 2 minutes at 50C,
10 minutes at 95C, 50 cycles of 15 seconds at 95C, and
1 minute at 60C. For transcripts of HMGA1, a set of
primers and probe was designed (forward primer: 50-GGA
CCA AAG GGA AGC AAA AA-30, reverse primer: 50-
TTC CTG GAG TTG TGG TGG TTT-30, probe: 6-FAM-
AAG GGT GCT GCC AAG ACC CGG-MGB). 18S rRNA
was chosen as endogenous control and detected with the
following primer/probe set: forward primer: 50-GGA TCC
ATT GGA GGG CAA AGT-30, reverse primer: 50-AAT
ATA CGC TAT TGG AGC TGG AAT TAC-30, probe:
TGC CAG CAG CCG C [10]. All reactions were run in
triplicate.
2.3. Analysis of gene expression
The relative expression was calculated by the DCt
method, using 18S rRNA as endogenous control and
choosing the HMGA1 expression of a myometrial sample
(of normal group) as calibrator. For statistical analyses,
Student’s t-test was used. P-values of #0.05 were consid-
ered to be signiﬁcant.
2.4. Fluorescence in situ hybridization
For determination of rearrangements involving 6p21 and
HMGA1, respectively, ﬂuorescence in situ hybridization
(FISH) was performed on metaphase preparations of the
cases myoma 36, myoma 110, myoma 121B, myoma
125A, and myoma 166A. For FISH, two overlapping clones
CTD-2522J1 (GenBank accession number AQ280064 and
AQ280066) and CTD-2510D13 (GenBank accession
number AQ264849 and AQ264850), both located distal to
HMGA1 in 6p21, and two overlapping clones CTD-2524P4
(GenBank accession number AQ310763 and AQ277896)
and RP11-140K17 (GenBank accession number AQ385566
and AQ385568), both located proximal to HMGA1, in 6p21
were used. CTD clones were obtained from Invitrogen
(Darmstadt, Germany); RP11-140K17 was obtained from
imaGenes (Berlin, Germany). DNA was isolated with the
Qiagen Plasmid Midi Kit (Qiagen, Hilden, Germany).
One microgram of isolated plasmid DNAwas labeled by
nick translation (Abbott Molecular, Wiesbaden, Germany)
either with SpectrumOrange-dUTP (CTD-2522J1 and
CTD-2510D13) or SpectrumGreen-dUTP (CTD-2524P4
and RP11-140K17) (Abbott Molecular). Treatment of
metaphases and subsequent FISH experiments were carried
out as described previously [11]. Twenty microliters of the
Fig. 2. FISH analysis with HMGA1 break-apart probes in four UL with 6p21 rearrangement. (A) Myoma 125A, (B) myoma 166A, (C) myoma 121B,
(D) myoma 110 (for karyotypes see Table 1). The green ﬂuorescent probes (CTD-2524P4 and RP11-140K17) located proximal to HMGA1, the red ﬂuores-
cent probes (CTD-2522J1 and CTD-2510D13) located distal to HMGA1. Arrows point to normal chromosomes 6 and the rearranged chromosomes.
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Table 1
Cytogenetic and molecular-cytogenetic data, results of relative HMGA1 and HMGA2 expression, and clinical data of all ULs. All tumors investigated were histologically typical leiomyomas.
Case no. Karyotype
Relative
HMGA1
expression
Relative
HMGA2
expression
Patient
age (y)
Tumor
size (cm)
HMGA1
expression
matching
myometrium
Single or
multiple
FISH analysis
for HMGA1
rearrangements
87 46,XX,t(6;14)(p23;q24)[6]/46,XX,t(6;14)(p23;q24),tas(14;21)(p13;q22)[11]/
46,XX[2]/47,XX,þ12[1]
0.5 0.6 63 d 1.7 Multiple ND
125A 46,XX,t(6;11)(p21;p15)[7]/46,XX[14] 32.0 2.7 42 2.5 2.3 Multiple Split signals
110 44,XX,der(1)t(1;?),der(3),der(5)t(5;?),6,der(11)?t(11;15)(q25;q22),del(15)
(q22),der(15)t(15;?),19[25]
33.2 1.6 44 4 NA Single Split signals
113C 46,XX,t(6;10)(p23;q23)[5]/46,XX[7] 34.0 11.4 53 3.5 NA Multiple ND
117D 46,XX,t(6;11)(p23;q21)[4]/46,XX[12] 41.2 26.0 39 4.5 NA Multiple ND
121B 42~46,X,X[6],1[19],t(1;8)(p22;q24)[11],der(1)[6],del(3)[3],add(6)[19],8
[6],der(8)[4],10[6],11[6],13[6],14[19],22[15],þmar1[18],þmar2
[18],þmar3[6],þmar[6][cp19]/46,XX[1]
63.3 0.8 38 3 NA Multiple Split signals
166A 46,XX,t(6;10)(p21;q22)[13]/46,XX[8] 110.4 1.29 d 3 NA Multiple Split signals
14B 46,XX[10] 2.8 3.8 46 d 8.5 Multiple ND
12B 46,XX[10] 3.1 2.4 41 d 1.0 Multiple ND
24 46,XX[20] 3.9 0.5 44 1 7.6 Multiple ND
27A 46,XX[10] 4.8 2.8 40 5 NA Multiple ND
20 46,XX[10] 5.1 0.6 36 d 1.2 Multiple ND
37D 46,XX[15] 10.0 12.9 43 2 15.4 Multiple ND
29 46,XX[21] 12.6 1.1 48 3.5 8.5 Multiple ND
36 46,XX[14] 23.2 10.7 39 6 6.9 Single No split signals
Abbreviations: e, unknown; ND, not done; NA, not available.
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break-apart probe was used per slide. Co-denaturation was
performed on a ThermoBrite (Abbott Molecular) for 7
minutes at 77C, followed by overnight hybridization in
a humidiﬁed chamber at 37C. Posthybridization was per-
formed at 70C for 2 minutes in 0.4 standard saline
citrate/0.3% NP-40. Metaphases were counterstained with
DAPI (40,6-diamidino-2-phenylindole; 0.75 mg/mL). Slides
were examined with an Axioskop 2 Plus ﬂuorescence
microscope (Carl Zeiss, Go¨ttingen, Germany). Images were
captured with a high-performance CCD camera (Visitron
Systems, Puchheim, Germany) and were edited with FISH
View (Applied Spectral Imaging, Migdal Ha’Emek, Israel).
Chromosomes were identiﬁed by inverted DAPI staining.
For each case, if possible, at least 10 metaphases were
analyzed, and 100 interphase nuclei were scored. Co-
localized signals (green/red) indicate a nonrearranged
breakpoint region, whereas separated green and orange
signals indicate a rearrangement of the chromosomal region
6p21 and HMGA1, respectively.
3. Results
In this study, seven ULs with chromosomal rearrange-
ments of 6p21 and eight karyotypically normal ULs as de-
tected by chromosome analysis of GTG-banded metaphases
and FISH analysis were subjected to real-time RT-PCR
analysis. According to the histological examination, no sign
of leiomyosarcoma or atypical leiomyoma was detected in
any of the cases (Fig. 1).
For identiﬁcation of 6p21 rearrangements involving
HMGA1 FISH on metaphase preparations and interphase
nuclei of ﬁve myomas (four cases with 6p rearrangement
or loss of one normal chromosome 6, respectively, and
one with apparently normal karyotype) was performed
with a HMGA1-speciﬁc break-apart probe. The results
revealed a signal pattern corresponding to a 6p21
rearrangement involving HMGA1 in all cases except for
that with a normal karyotype (numbers 110, 121B, 125A,
and 166A; Fig. 2AeD).
The expression of HMGA1 mRNA in seven ULs with
6p21 rearrangement was compared to that in eight samples
of UL with an apparently normal karyotype, which served
as controls (Table 1). For nine of these samples, matching
myometrium was available. Two myometrial samples be-
longed to ﬁbroids of the 6p group, and the remaining
tissues belonged to ﬁbroids of the normal group. The
average relative expression level in the 6p group was 45-
fold compared to its expression in a myometrium sample
of normal group as calibrator and differed signiﬁcantly
from that in the control group (8.2-fold increase). As to
the expression in the individual tumors, HMGA1 expres-
sion, with one exception, clearly distinguishes between
both karyotypic groups (Fig. 3). In the exception, case
87, no unusually high percentage of metaphases with
normal karyotype could be detected, which may explain
the low expression of HMGA1 observed. Regarding
the expression of HMGA1 in UL and matching myome-
trium, there were no signiﬁcant differences in the normal
group.
Next, we analyzed whether the expression of HMGA1
correlates with the expression of HMGA2. No evidence
for such a correlation was obtained (Fig. 3).
4. Discussion
ULs are by far the most common gynecological tumors,
occurring in at least 70e80% of all women in their repro-
ductive years [12e14]. Cytogenetic subtypes have been
identiﬁed that may correlate with a different molecular
pathogenesis of the disease. So far, the best-investigated
group is characterized by 12q14~15 changes associated
with a strong overexpression of HMGA2 [3,15]. The
Fig. 3. Relative quantiﬁcation of the HMGA1 and HMGA2 expression in normal and aberrant uterine leiomyomas (ULs).
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overexpression of the stem-cell chromatin-associated
protein HMGA2 ﬁts well with important characteristics of
UL growth. A much smaller subset of UL is characterized
by 6p21 rearrangements leading to the upregulation of
a closely related protein of the HMGA family (i.e.,
HMGA1). Likely activation of either of both genes and
the abundance of their proteins, respectively, leads to an
almost identical histopathologic phenotype of the tumors
commonly referred as leiomyomas.
However, what distinguishes tumors of both types is the
level of overexpression of HMGA genes compared to myo-
metrium. Whereas the average upregulation of HMGA2 in
case of 12q14~15 aberrations is in range of 3,000-fold [3],
even when omitting the outlier represented by case 87, upre-
gulation of HMGA1 due to 6p21 rearrangements is on
average 45-fold and raise up to amaximum of only 52.4-fold.
We had recently been able to show that most cytogenet-
ically normal leiomyomas show subtle changes of the
HMGA2 level compared to the matching myometrium as
well [3]. Some recent studies have correlated HMGA2 with
stemness of mesenchymal cells and stem cell self-renewal
[4,16]. Although similar studies are lacking for HMGA1,
it is tempting to assume that the translocation products of
both genes can shift mesenchymal stem cells or progenitors
of smooth muscle cells and other mesenchyme-derived
cells back to a higher self-renewing potential. Nevertheless,
we were recently able to show that there is no correlation
between the expression of Ki-67 and HMGA2 [17]. Thus,
the exact mechanism by which increased levels of HMGA
proteins contribute to benign tumorigenesis still remains to
be elucidated. However, HMGA1 can be assumed to have
the ability to replace, at least in part, the function of
HMGA2 and vice versa. The proteins of both genes are
highly charged DNA-binding proteins that show abundant
expression in embryonic cells but greatly decreased expres-
sion in most adult cells. They share a high homology in
their DNA-interacting domains; despite their apparent
differences in interaction partners [18], this may explain
why knockout for neither gene alone is lethal.
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The stem cell chromatin associated protein HMGA2 is discussed as a mutagenic 
protein inducing genomic instability. Nevertheless, it is unlikely that HMGA2 which is 
abundantly expressed during embryonic and fetal life impairs the integrity and 
stability of genome. We have addressed this apparent contradiction by considering 
the increased number of metaphases with single cell aberrations as a hallmark of 
genomic instability. From the results, there was no evidence for an increased 
genomic instability in the group of uterine leiomyomas with 12q14~15 
rearrangements leading to HMGA2 overexpression compared with the group of 
normal myomas. 
Recently, some evidence has been presented (Li et al., 2009) that the chromatin 
associated high mobility AT-hook 2 (HMGA2) can act as a mutagenic protein 
inducing DNA-double strand breaks as well as polyploidy. However, the findings have 
been challenged because in embryonic stem cells and a couple of highly frequent 
benign tumors as e.g. leiomyomas, lipomas, and pulmonary chondroid hamartomas 
an abundant expression of HMGA2 is not accompanied by a marked genomic 
instability or an increased tendency of malignant transformation (Sandberg, 2005; 
Morton, 1998). Thus, it has been proposed that HMGA2 may contribute to genomic 
instability only very high concentrations. However, to the best of our knowledge it has 
not been investigated as yet if in benign tumors an over expression of HMGA2
correlates with increased genomic instability as reflected by an increased number of 
metaphases with single cell aberrations. One type of tumor offering good chances for 
this type of investigations are uterine leiomyomas (UL). Whereas the majority of UL 
display an apparently normal karyotype. UL with clonal aberrations targeting the 
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HMGA2-locus (Ashar et al., 1995; Schoenmakers et al., 1995) leading to its 
overexpression (Tallini et al., 2000; Gross et al., 2003; Klemke et al., 2009) are a 
frequently occurring subtype. Herein we have compared the frequency of single cell 
aberrations in 20 UL with 12q14~15 aberrations (Fig.1: (a) and (b)) with that of 184 
UL with an apparently normal karyotype (Fig.1: (d)). All tumors included in this study 
were additionally analyzed by qRT-PCR for their expression of HMGA2 mRNA in 
order to detect hidden HMGA2 rearrangements (Fig.2). Within the 12q14~15 group of 
UL the average HMGA2 expression was found to be 102-fold higher than in the 
group with a normal karyotype. Nevertheless, there was no evidence for an increased 
genomic instability in the former group (Tab. 1) nor was there any evidence for an 
increase rate of polyploid cells. 
It seems plausible to assume that the cells having 12q14~15 abnormalities protect 
the genome despite their high HMGA2. Narita and colleagues mentioned that the 
HMGA proteins also act in tumor suppressor networks by having a role in cellular 
senescence and heterochromatin formation (Narita et al., 2006). The study by 
Markowski et al., (2010) revealed a high expression of senescence-associated p19Arf
in the presence of overexpression of HMGA2 in UL with 12q14~15 rearrangements. 
Results of this study identify the p19Arf-TP53-CDKN1A pathway as a balancer in the 
growth and genomic stability of UL in presence of a high level of HMGA2. Therefore, 
the role of tumor suppressor protein p53 in senescence and genetic stability should 
be attended. The data by Izadpanah et al. (2008) presented that there is a 
coincidence between the arrest in the S phase of the cell cycle, detected in the long-
term in vitro culture of human mesenchymal stem cells (MSCs) and the considerably 
suppressed expression of p53. Therefore, seems 12q14~15 aberrations leading to an 
overexpression of HMGA2 do not increase the instability of genome in uterine 
leiomyomas. 
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(a)  (b)  
(c) (d) 
Fig.1: Karyograms of myomas including single cell aberration or chrb/chtb. 
(a) Myoma 612: 45,XX,r(1),t(12;14),der(15)t(15;18),-18; (b) Myoma 612: 42,XX, der(1)r(1;?),-
4,dic(11;?;15), t(12;14) (q15;q24),-15,-15,-20; (c) Myoma 551.2: 48,XX,+4,+12, chrb(12)(p), 
chtb(13)(q); (d) Myoma 590.1: 46,XX, Chrb(3)(q), Chtb(3)(p). 
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Fig. 2: RQ HMGA2 expression in leiomyomas. 
Green bars: UL without single aberration or chrb/chtb; red bars: UL with single aberration or chrb/chtb. 
Tab. 1: Results of the analysis of the metaphases in different cytogenetic subgroups. 
Cytogenetic 
group 
All affected 
myomas with 
single aberration 
or chrb/chtb 
12q aberrant 
myomas 
without single 
aberration or 
chrb/chtb 
Normal 
myomas 
without single 
aberration or 
chrb/chtb 
All 12q 
aberrant 
myomas 
All 
normal 
myomas 
Total samples 46 16 151 20 184 
Range of 
analysed 
metaphases 
6-29 6-27 5-27 6-27 5-29 
Total analysed 
metaphases 740 270 1915 341 2431 
Average of 
analysed 
metaphases 
16 17 13 17 13 
Total 
karyotyped 
metaphases 
402 144 930 180 1205 
Average 
karyotyped 
metaphases 
9 9 6 9 7 
Total affected 
samples 46 0 0 4 33 
Percentage of 
Total affected 
samples 
100% 0% 0% 20% 17.9% 
Total affected 
metaphases 63 0 0 6 45 
Percentage of 
Total affected 
metaphases 
8.5% 0% 0% 1.76% 1.85% 
Abbreviations: chrb/chtb: chromosome break/chromatid break. 
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